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Nutlin-3a is an MDM2-p53 interaction antagonist that is under investigation in 
preclinical models for a variety of pediatric malignancies, including neuroblastoma, 
retinoblastoma, leukemia, and rhabdomyosarcoma. In the current research, we conducted 
preclinical pharmacology studies of nutlin-3a to evaluate the synergistic effect of the 
nutlin-3a and topotecan combination on neuroblastoma cell growth, to assess the effect of 
nutlin-3a on breast cancer resistance protein (BCRP), and to characterize the disposition 
of nutlin-3a in the mouse plasma and multiple tissues.  
 
Activating the p53 pathway might offer a new therapy for neuroblastoma. In the 
first part of the study, we assessed the effect of nutlin-3a on the cell viability of 
neuroblastoma both as a single agent and in combination with topotecan. We showed that 
targeting MDM2-p53 interaction using nutlin-3a reduced cell growth in neuroblastoma 
cells. p53 wild-type cells were much more sensitive to nutlin-3a treatment compared to 
p53 mutant cells. When nutlin-3a was combined with topotecan, a synergistic effect on 
neuroblastoma cell growth was observed. To explore the mechanism of synergy, we 
performed quantitative real-time polymerase chain reaction (qRT-PCR) and western blot 
analysis and found reduction of P-gp expression at both the message level and protein 
level in p53 wild-type neuroblastoma cells. This is the first study showing the synergistic 
effect of nutlin-3a in combination with topotecan in neuroblastoma cells and the 
reduction of P-gp expression by nutlin-3a in p53 wild-type cells. 
 
Although nutlin-3a is currently under pre-clinical investigation as a p53 
reactivation agent, it has been recently demonstrated also to have p53 independent 
actions in cancer cells. In the second part of the study, we first reported that nutlin-3a can 
inhibit the efflux function of BCRP. We observed that although the nutlin-3a IC50 did not 
differ between BCRP over-expressing and vector control cells, nutlin-3a treatment 
significantly potentiated the cells to treatment with the BCRP substrate mitoxantrone. 
Combination index calculations suggested synergism between nutlin-3a and mitoxantrone 
in cell lines over-expressing BCRP. Upon further investigation, it was confirmed that 
nutlin-3a increased the intracellular accumulation of BCRP substrates such as 
mitoxantrone and Hoechst 33342 in cells expressing functional BCRP without altering 
the expression level or localization of BCRP. Interestingly, nutlin-3b, considered 
virtually "inactive" in disrupting the MDM2/p53 interaction, reversed Hoechst 33342 
efflux with the same potency as nutlin-3a. Intracellular accumulation and bi-directional 
transport studies using MDCKII cells suggested that nutlin-3a is not a substrate of BCRP. 
Additionally, an ATPase assay using Sf9 insect cell membranes over-expressing 
wild-type BCRP indicated that nutlin-3a inhibits BCRP ATPase activity in a 
dose-dependent fashion. In conclusion, our studies demonstrate that nutlin-3a inhibits 
BCRP efflux function, which consequently reverses BCRP-related drug resistance. 
 
Understanding drug disposition is critical in preclinical drug development. In the 
third part of the study, we used physiologically-based pharmacokinetic (PBPK) modeling 
to characterize the disposition of nutlin-3a in mice. Plasma protein binding and blood 
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partitioning were assessed by in vitro studies. After intravenous (10 and 20 mg/kg) and 
oral (50, 100, and 200 mg/kg) dosing, tissue concentrations of nutlin-3a were determined 
in plasma, liver, spleen, intestine, muscle, lung, adipose, bone marrow, adrenal gland, 
brain, retina, and vitreous fluid. The PBPK model was simultaneously fit to all 
pharmacokinetic data using NONMEM. Nutlin-3a exhibited nonlinear binding to murine 
plasma proteins, with the unbound fraction ranging from 0.7 to 11.8%. Nutlin-3a 
disposition was characterized by rapid absorption with peak plasma concentrations at 
approximately 2 h and biphasic elimination consistent with a saturable clearance process. 
The final PBPK model successfully described the plasma and tissue disposition of 
nutlin-3a. Simulations suggested high bioavailability, rapid attainment of steady state, 
and little accumulation when administered once or twice daily at dosages up to 400 
mg/kg. The final model was used to perform simulations of unbound tissue 
concentrations to determine which dosing regimens are appropriate for preclinical models 
of several pediatric malignancies.  
 
 In conclusion, our results showed that nutlin-3a synergistically inhibited the 
growth of neuroblastoma cells when combined with topotecan. Nutlin-3a reversed 
BCRP-mediated drug resistance by inhibiting the function of BCRP. A PBPK model was 
successfully established to describe the disposition of nutlin-3a in plasma and tissues of 
interest for pediatric malignancies.  
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1.1. Introduction of Nutlin-3a 
 
1.1.1. Restoring p53 as a therapeutic strategy 
 
Studies from the past three decades show tumor suppressor protein p53 plays 
important roles in organizing cell defense against cancerous transformation. In responses 
to stress conditions such as irradiation, DNA damages, and hypoxia, p53 works as a 
potent transcription factor that activates downstream genes, leading to cell cycle arrest, 
apoptosis, and inhibition of angiogenesis [1]. p53 can also exert a pro-apoptotic function 
independent of transcriptional functions [2, 3]. 
 
Tumor suppressor p53 is mutated in half of the human tumors [4]. In those tumors 
that retain wild-type p53, p53 is tightly regulated and maintained at low or undetectable 
levels. p53 protein has a short half-life of ~20 minutes [5] due to the key negative 
regulator oncogene murine double minute-2 (MDM2). MDM2 (also known as HDM2) 
acts as an E3 ubiquitin ligase that facilitates the export of p53 from the nucleus to the 
cytoplasm and targets p53 for ubiquitin-dependent proteasome degradation [6, 7]. In 
addition, MDM2 inhibits p53 function by direct binding to the transcriptional binding site 
of p53, thereby preventing its interaction with the transcription machinery [8]. p53 and 
MDM2 interact to form an auto-regulatory loop, where increased p53 transcriptionally 
activates MDM2 and the latter in turn decreases the level of p53 [9] (Figure 1-1). 
MDMX (also known as a MDM4 or HDMX), sharing substantial structural homology 
with MDM2, also has an important role in regulating p53 [10-12]. In addition to 
inhibiting the transcriptional activity of p53, MDMX forms a heterocomplex with MDM2 
that potentiates the ubiquitylation and degradation of p53 [13, 14]. Unlike MDM2, 
MDMX is not a transcriptional target of p53. Binding of MDMX with MDM2 can cause 
ubiquitination and degradation of MDMX.  
 
Considering the important roles of MDM2/MDMX in p53 stability and function, 
restoration of the impaired function of p53 by inhibiting MDM2/MDMX was considered 
an attractive strategy to treat tumors with wild-type p53 [15]. Several inhibitors of 
MDM2/MDMX have been discovered and are currently under investigations. For 
example, a phase I study for JNJ-26854165 (developed by Johnson & Johnson, USA) in 
patients with advanced stage or refractory solid tumors (ClinicalTrials.gov identifier 
number: NCT00676910) was completed last year. Phase I clinical trials for RO5045337 
(RG7112, developed by F. Hoffmann-La Roche, USA) are ongoing for patients with 
solid tumors (ClinicalTrials.gov identifier numbers: NCT00559533 and NCT01164033), 
hematologic neoplasms (ClinicalTrials.gov identifier number: NCT00623870), and 
liposarcomas (ClinicalTrials.gov identifier number: NCT01143740). Other compounds 
such as MI-219 [16] (also known as AT219), nutlin-3a [17], SJ-172550 [18], and 











1.1.2. Nutlin-3a mechanism of action 
 
In 2004, Vassilev and colleagues reported a group of imidazoline compounds 
called nutlins are able to inhibit MDM2-p53 binding with high binding potency and 
selectivity [17]. Nutlin-3 (Figure 1-2) is the most potent compound among the three 
nutlins (nutlin-1, nutlin-2, and nutlin-3). So far, nutlin-3 is the most widely published 
small molecule inhibitor of MDM2/MDMX-p53 interaction. Nutlin-3 is a racemic 
mixture of nutlin-3a (active enantiomer) and nutlin-3b (inactive enantiomer). The binding 
affinity for nutlin-3a to MDM2 is 150-fold higher than nutlin-3b [17].  
 
Successful development of nutlin is based on understanding the structural biology 
of the p53-MDM2 interaction. Kussie and colleagues reported a relative deep p53 
binding pocket on the surface of the MDM2 protein [20]. Specifically, they found that 
only three amino acid residues (Phe19, Trp23, and Leu26) of p53 are critical to the 
binding and fit tightly in the MDM2 binding pocket. This finding made de novo synthesis 
of small molecule inhibitors of the MDM2-p53 interaction possible. Nutlins were 
generated by combing structure-based screening of the 3D database, high-throughput 
screening of large chemical libraries, and extensive chemical modifications of the lead 
compounds. Crystal structure data of MDM2-nutlin complex proved the binding of nutlin 
to the p53 pocket [17, 21]. The ethoxy group on the nutlin occupies the position of 
Phe19, the bromophenyl group occupies the position of Trp23, and the others occupy the 
position of Leu26 [22]. Since MDM2 and MDMX share structure/sequence similarity and 
MDMX binds to the similar region of p53 [23], nutlin-3 also binds to MDMX with lower 
affinity (Figure 1-3) [17, 24]. 
 
 
1.1.3. Reactivation of the p53 pathway by nutlin-3a in vitro
Since 2004, many in vitro studies have been conducted to examine the effect of 
nutlin-3 on cell cycle arrest and apoptosis. For example, the effect of nutlin-3a and 
nutlin-3b (1.25-10 μM) on cell cycle arrest was examined in a panel of cancer cell lines 
from different tumor types, including colorectal (HCT116 and RKO), lung (H460 and 
A549), breast (MCF7), prostate (LnCaP and 22Rv1), melanoma (LOX), osteosarcoma 
(SJSA-1), and renal cancer (A498) [25]. 24 hour treatment of nutlin-3a induced a 
reduction/depletion of the S-phase fraction, as well as G1 and G2 arrest in all the p53 
wild-type cell lines tested. Expression of p21, an essential element of p53-induced cell 
cycle arrest, increased after nutlin-3a treatment. In contrast, these effects were not 
observed in inactive enantiomer nutlin-3b treatment groups. Colon cancer cells with 
mutant p53 (HT29) did not respond to nutlin-3a treatment in vitro and in vivo [25].  
 
In contrast to cell cycle arrest, the pro-apoptotic effect is more variable. Apoptosis 
after nutlin-3a (or -3b) treatment (24~72 hours) was evaluated by Annexin V assay [25]. 
Annexin V positive fractions varied among p53 wild-type cells from as high as 80% 
(SJSA-1) to 10% (A549 and HCT116). Since incubation cells with doxorubicin (250 nM) 
for 48 h led to a dramatic increase of the Annexin V-positive cell fraction in all of the 
tested lines (including the cell line that had low Annexin V-positive faction after nutlin-3 
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Figure 1-3.  Nutlin-3a binds to the MDM2-p53 and MDMX-p53 binding pockets 
 
Source: Reprinted with permission. Laurie, N.A., et al., Inactivation of the p53 pathway 
in retinoblastoma. Nature, 2006. 444(7115): p. 61-6.  
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treatment), the authors concluded that the low apoptotic level observed after nutlin-3 
treatment is not caused by defects in the general components of the apoptotic machinery; 
rather these cells might have defects in p53-dependent apoptotic signaling. 
 
Studies suggested correlations between high MDM2 expression and strong 
apoptosis response when p53 wild-type cells are treated with nutlin-3. A significant 
correlation between MDM2 expression levels and sensitivity to nutlin-3 in p53 wild-type 
cells was observed in 18 ALL cell lines and 30 primary leukemia samples [26]. Nutlin-3 
potently killed wild-type p53 ALL cells over-expressing MDM2. Osteosarcoma cells 
SJSA-1 and MHM, p53 wild-type cells with 25- and 10- fold MDM2 gene amplification 
and high MDM2 expression, had the strongest apoptosis response among a panel of 10 
p53 wild-type cell lines tested by Annexin-V and microarray analysis [25]. LNCaP 
(prostate cancer), 22Rv1 (prostate cancer), and RKO (colon cancer) cells with a single 
copy of MDM2 gene had intermediate levels of apoptotic response. HCT-116 (colon 
cancer) and U20S (osteosarcoma) cell lines, lacking the MDM2 gene amplification, had 
the lowest apoptosis response. Thus, MDM2 expression in tumors may be a valuable 
response biomarker in the clinic. However, studies for MDM2 might not directly translate 
to MDMX. In fact, Hu and colleges reported that MDMX over-expression prevents p53 
activation by nutlin-3 [27].  
 
In addition, some other characteristics of nutlin-3a are worth mentioning: 
1).Unlike radiation and traditional chemotherapy drugs, nutlin-3 activates p53 in a 
nongenotoxic manner. 2). Nutlin-3 induces apoptosis in p53 wild-type cancer cells; 
however, it only causes cell cycle arrest in normal cells, which may help protect normal 
cells from cytotoxic chemotherapies. Thus nutlin-3 was proposed to act as a 
chemo-protective agent [28]. 3). Multiple studies have suggested synergistic/sensitizing 
effects of nutlin-3 with radiation [29] or other chemotherapeutic drugs including (but not 
limited to) topotecan (in retinoblastoma cells) [24], doxorubicin and selumetinib (in acute 
myeloid leukemia cells) [30, 31], chlorambucil, doxorubicin, fludarabine, dasatinib (in 
chronic lymphocytic leukemia cells) [32-35], R-roscovitine (in neuroblastoma cells) [36], 
vincristine, actinomycin D, doxorubicin, etoposide (in Ewing sarcoma cells), and 
bortezomib (in myeloma, thyroid, breast, and prostate carcinomas and colon carcinoma 
cells) [37, 38].  
 
 
1.1.4. In vivo anti-tumor effect of nutlin-3a 
 
In vivo, nutlin-3a monotherapy demonstrated anti-tumor efficacy in preclinical 
models of human osteosarcoma, prostate cancer, retinoblastoma, KSHV lymphoma, and 
neuroblastoma with wild-type p53 [17, 24, 25, 39-41]. Vassilev et al. first reported the in 
vivo activity of nutlin-3 in nude mice bearing subcutaneous human osteosarcoma 
xenograft (SJSA-1). Nutlin-3 (po. 200mg/kg BID for 3 weeks) was well tolerated without 
causing significant weight loss or any gross abnormalities upon necropsy at the end of the 
treatment. Compared to the vehicle control group, nutlin-3 treatment resulted in 90% 




Tovar et al. conducted in vivo study of nutlin-3a in nude mice bearing SJSA-1 
(osteosarcoma), MHM (osteosarcoma), LNCaP (prostate cancer), 22Rv1 (prostate 
cancer) and HT29 (colon cancer) tumors [25]. SJSA-1-bearing mice were treated with an 
oral dose of 50mg/kg, 100mg/kg or 200mg/kg nutlin-3a twice daily for 3 weeks. 
Nutlin-3a dose dependently suppressed SJSA-1 tumor growth, with substantial tumor 
shrinkage observed in the 200mg/kg treatment group. The 200 mg/kg oral nutlin-3a twice 
daily regimen was also efficacious in MHM (3 weeks treatment), LNCaP (2 weeks 
treatment), and 22Rv1 (2 weeks treatment) models with average tumor growth inhibition 
> 98%. In p53 mutant HT29 xenograft, nutlin-3a did not reduce the tumor size. The data 
showed a reasonable correlation between in vitro and in vivo tumor response. Similar to 
the report from Vassilev et al., no weight loss or significant pathological changes were 
observed during the study.  
 
Laurie et al. conducted the first in vivo study to assess the effect of nutlin-3 on 
retinoblastoma [24]. Subconjunctival injections of 1 μl nutlin-3 (170 mM) and topotecan 
(2 mM) both as a single agent and in combination were administered into each eye of 
tumor-bearing mice daily for 5 days. Total treatment amount per eye was 85 pmol 
nutlin-3 and 2 nmol topotecan. Both nutlin-3 and topotecan were effective as a single 
agent in the Y79-luc orthotopic model. The combination of subconjunctival topotecan 
and nutlin-3 resulted in an 82-fold tumor burden reduction with no ocular or systemic 
side-effects. Brennan et al. recently reported a study aimed to identify better 
chemotherapeutic combinations for the treatment of retinoblastoma in genetically 
engineered mouse models and orthotopic xenograft models of human retinoblastoma 
[42]. SCID mice bearing SJ-39 retinoblastoma tumor cells received 
vincristine/toposide/carboplatin, carboplatin(subconj)/topotecan(syst), or 
carboplatin(subconj)/topotecan(syst) alternating with nutlin-3a(OC)/topotecan(syst). The 
nutlin-3a(OC)/topotecan(syst)-containing group showed significantly better response. 
Subconjunctival administrations of nutlin-3a alone or in combination with topotecan were 
well tolerated without ocular or systemic toxicity. 
 
Van Maerken et al. reported the effect of nutlin-3 on nude mice bearing 
chemo-resistant, MYCN-amplified neuroblastoma [43]. 200mg/kg oral nutlin-3 twice 
daily treatment reduced tumor growth and metastasis in the p53 wild-type 
UKF-NB-3rDOX20 xenograft without causing signs of toxicity. No treatment effect was 
observed in p53 mutant UKF-NB-3rVCR10 xenograft, suggesting p53 status significantly 
influences the in vivo response to nutlin-3 treatment.  
 
 
1.2. ABC Transporters and Drug Interaction 
 
 
1.2.1. ABC transporter family 
 
Transporters are membrane proteins that play important roles in controlling the 
influx and efflux of ions, glucose, bile acids, vitamins, hormones, lipids, fatty acids, 
toxins, and drugs across cell membranes [44, 45]. 5~7% ( > 2,000) of all human genes 
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code for transporters or transporter-related proteins [46]. Among all the transporters, 
ATP-binding cassette (ABC) and Solute carrier (SLC) transporters are two major families 
of membrane proteins that are important for transporting drugs. So far, more than 400 
membrane transporters in these two families have been annotated in the human genome 
[47].  
 
ABC transporters are a family of active transporters relying on adenosine 
triphosphate (ATP) hydrolysis to pump substrates in (influx) and out (efflux) of the cell 
membranes. In prokaryotes, ABC transporters function as both uptake transporters and 
efflux transporters. However, in eukaryotes, ABC transporters function only as efflux 
transporters [48, 49]. The ABC gene family is composed of 49 genes in 8 subfamilies in 
the human genome [45]. The basic structure of ABC transporters contains two types of 
domains: nucleotide binding domain (NBD) and transmembrane domain (TMD) (Figure 
1-4) [50]. The NBD, the conserved domain among the ABC transporters, plays a critical 
role in ATP binding and hydrolysis. Unlike NBD, TMD varies significantly in terms of 
the sequence, length, and number of transmembrane helices [51]. TMD binds to 
substrates and determines the transporter specificity through substrate-binding sites [52]. 
Among the ABC family of transporters, P-glycoprotein (P-gp/MDR1/ABCB1), multidrug 
resistance protein 1 (MRP1/ABCC1) and breast cancer resistance protein 
(BCRP/MXR/ABCG2) are three major members associated with multidrug resistance 
[53].  
 
P-gp, the product of MDR1 (or ABCB1) gene, was one of the first members of the 
ABC superfamily studied. Long before P-gp was discovered, it had been reported that 
incubating cancer cells with chemotherapy agents will generate subline cells that are 
resistant to not only the selecting agents but also to other structurally different agents [53-
55]. 10 years after the first report of the 170 kDa glycoprotein [53-55], Roninson et al. 
reported the cloning of the gene encoding P-gp [56]. P-gp contains 2 NBDs and 12 TMDs 
(Figure 1-4) [50]. In addition to tumor cells, P-gp is also expressed in multiple normal 
organs/cells, such as intestinal enterocytes, kidney proximal tubule, hepatocytes 
(canalicular), and brain capillary endothelial cells. P-gp transports a broad variety of 
substrates out of the cells, including endogenous substrates, and drugs such as vincristine, 
vinblastine, doxorubicin, topotecan, mitoxantrone, etoposide, paclitaxel, docetaxel, and 
digoxin. 
 
BCRP, a 72-kDa protein product of ABCG2 gene, is also called ABCP or MXR. 
As indicated by its most commonly used name, BCRP was identified from a 
multidrug-resistant human breast cancer subline (MCF-7/AdrVp) in 1998. In 1999, it was 
cloned from mitoxantrone selected cells; thus it was also named mitoxantrone resistance 
protein (MXR) [57]. Interestingly, the clones from the drug selected cells containing 
single nucleotide mutations at the position of amino acid 482 (R for wild-type protein, T 
in BCRP, and G in MXR), causing changes in substrate specificity [50, 58]. Unlike P-gp 
and MRPs, BCRP is a “half-transporter.” It contains only 1 NBDs and 6 TMDs (Figure
1-4) [50]. BCRP is expressed in tumor cells, hematopoietic stem cells, placenta, small 
intestine, mammary glands, testis, liver, blood brain barrier, and the adrenal gland  
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Figure 1-4.  The structures of three categories of ABC transporter
a. ABC transporters such as multidrug resistance MDR1 and multidrug resistance 
associated protein 4 (MRP4) have 12 transmembrane domains and two ATP binding 
sites.
 
b. The structures of MRP1, 2, 3 and 6 are similar in that they possess two ATP binding 
regions. They also contain an additional domain that is composed of five transmembrane 
segments at the amino-terminal end, giving them a total of 17 transmembrane domains. 
 
c. The ‘half-transporter’ ABCG2 contains 6 transmembrane domains and one 
ATP-binding region — in this case, on the amino-terminal side (N) of the transmembrane 
domain. In other ‘half-transporters’, such as the transporter associated with antigen 
processing, the ATP-binding cassette is found on the carboxy-terminal (C) side of the 
transmembrane domain. Half-transporters are thought to homodimerize or heterodimerize 
to function.  
 
Source: Reprinted with permission. Gottesman, M.M., T. Fojo, and S.E. Bates, Multidrug 
resistance in cancer: role of ATP-dependent transporters. Nature Reviews. Cancer, 2002. 




[47, 50, 59]. BCRP transports endogenous substrates and drugs such as mitoxantrone, 
topotecan, SN-38, methotrexate, doxorubicin, and daunorubicin [50, 58]. 
 
In addition, P-gp, BCRP, and many other members of ABC transporter family 
play important roles in absorption, distribution, metabolism, and excretion (ADME) of 
chemotherapy drugs that are substrates of the ABC transporters. 
 
 
1.2.2. Role of ABC transporter in drug ADME  
 
At least 10 ABC transporters (P-gp, MDR3, BSEP, MRP1, MRP2, MRP3, MRP4, 
MRP5, MRP6, and BCRP) are involved in drug disposition [47, 59]. They are located on 
the apical or basolateral side of endothelial or epithelial cells in various organs (Table
1-1) [47, 59].  
 
 
1.2.2.1. Effects on drug absorption. ABC transporters located on the apical 
membrane of enterocytes, such as P-gp, MRP2, and BCRP [47], can pump their 
substrates back to the intestinal lumen—thus limiting the absorption of some orally 
administered drugs. For example, paclitaxel bioavailability in P-gp knockout mice 
increased from 11.2% to 35.2 % compared to the wild-type mice [60]. Docetaxel 
bioavailability increased from 3.6% to 22.7% in P-gp knockout mice compared to the 
wild-type mice [61]. Leggas et al. reported that topotecan bioavailability increased in 
both BCRP and P-gp knockout mice and further increased with gefitinib (an inhibitor of 
BCRP and P-gp) treatment [62]. MRP1 and MRP3 are expressed at the basolateral side. 
Thus, theoretically, they could increase absorption of some drugs. A recent study 
suggests that MRP1 might facilitate the absorption of cobalamin in mice [63]. Several 
ABC transporters are expressed in the lungs and therefore may potentially affect the 
absorption of inhaled drugs. However, in vivo evidence is needed to support this 
hypothesis [64]. 
 
1.2.2.2. Effects on drug distribution. ABC transporters located on the 
blood-brain barrier (BBB), blood-cerebrospinal fluid (CSF) barrier, blood-placental 
barrier, blood-testis barrier [65], blood-retina barrier [66], and heart [67] can limit the 
drug distribution to corresponding organs. BBB is a good example on how ABC 
transporters affect drug distribution. Before the 1990s, the BBB was considered a 
physical barrier formed by tight junctions between brain capillary endothelial cells 
(BCEC) that lack fenestrations [68]. Now, it is well established that P-gp on the apical 
membrane of BCECs is also an important component of BBB. The brain accumulation of 
many P-gp substrates can be much higher in P-gp knock-out mice than in wild-type mice, 
and inhibiting P-gp can increase the brain distribution. For example, amprenavir, an HIV 
protease inhibitor, is a substrate of P-gp [69] but not a substrate of BCRP [70]. Brain 
concentrations of [14C]-amprenavir were 27-fold higher in mdr1a-/-/1b-/- mice compared 
to the wild-type mice. In the presence of P-gp and BCRP inhibitor GF120918, a 13-fold 
increase of [14C]-amprenavir brain concentrations compared to the vehicle control treated 
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Table 1-1. Important ABC transporters 
 
Name Polarity Locations 
P-gp Apical Kidney, adrenal gland, liver, pancreas, intestine, 
lung, BBB, placenta, prostate, skin, heart, 
skeletal muscle, ovary, testis, retina 
MDR3 Apical Liver 
BCRP Apical Placenta, mammary gland, BBB, liver, intestine, 
kidney, lung 
MRP1 Apical (placenta, BBB) 
Basolateral (others) 
Kidney, lung, testis, skeletal muscle, heart, 
placenta, liver, intestine, brain 
MRP2 Apical Liver, kidney, intestine, placenta 
MRP3 Basolateral Adrenal gland, intestine, pancreas, intestine, 
gallbladder, placenta, liver, kidney 
MRP4 Apical (kidney, BBB) 
Basolateral (prostate, 
choroid plexus) 
Prostate, kidney, liver, brain, pancreas 
MRP5 Apical (BBB) Basolateral 
(others) 
Heart, brain, neurons 
MRP6 Basolateral Liver, kidney, skin, lung, heart, intestine, 
pancreas, stomach 
BSEP Apical Liver 
 
Sources: Adapted with permission.  
1. Giacomini, K.M., et al., Membrane transporters in drug development. Nature Reviews. 
Drug Discovery, 2010. 9(3): p. 215-36. 
2. Marquez, B. and F. Van Bambeke, ABC multidrug transporters: target for modulation 





group was observed [71]. Blood concentrations of [14C]-amprenavir increased 1.1-fold 
and 2-fold in mdr1a-/-/1b-/- mice and GF120918 treated mice, respectively [71]. Although 
less prominent than P-gp, BCRP and some MRPs are also involved in the function of 
BBB. These transporters can protect the brain from peripheral toxins but also hinder the 
delivery of central nervous system (CNS) drugs.  
 
 
1.2.2.3. Effects on drug metabolism. ABC transporters do not metabolize drugs 
themselves, but they affect metabolic clearance remarkably through interplay with drug 
metabolism enzymes. It has been proposed that ABC transporters and drug metabolism 
enzymes have undergone co-evolution toward a united xenobiotic defense system [45]. 
The relationship between P-gp and CYP3A4 is considered evidence of this theory. The 
ABCB1 gene (encodes for P-gp) and the cluster of CYP3A4 genes are both at 
chromosome 7 and just 119kb apart [45]. In addition, both genes are regulated by 
pregnane X receptor (PXR). P-gp and CYP3A4 also share similar substrate specificity 
and are co-localized in important drug-eliminating organs such as liver, kidney, intestine, 
and lung [45, 72]. The most well-known effect of P-gp on CYP3A4 is exemplified by the 
intestinal first-pass metabolism. As mentioned, P-gp in enterocytes can pump back its 
substrate into the gut lumen, thus decreasing the fraction of absorption (fa). In addition, 
the P-gp-mediated efflux also helps decrease the likelihood of CYP3A4 saturation by 
lowering the intracellular peak drug concentration. The effluxed drug may undergo 
re-absorption, but the overall effect will be more opportunities for the CYP3A4 to 
metabolize the substrate drug. Therefore, P-gp can indirectly decrease the fraction of the 
intact drug escaping gut metabolism (fg) [59, 68, 73]. Drug conjugates formed by Phase 
II drug metabolism enzymes, e.g., UDP-glucuronosyltransferases (UGTs), 
sulfotransferases (SULTs), and glutathione S-transferases (GSTs), can also be effluxed 
by MRP2 and BCRP. This process is sometimes called “Phase III drug metabolism”. 
 
 
1.2.2.4. Effects on drug excretion. Drug excretion refers to the final removal of 
intact drugs or their metabolites from the body. Although this step can take place in 
several organs, biliary excretion and renal excretion are the most important routes [59]. 
Different ABC transporters are localized at the canicular or sinusoidal membrane of 
hepatocytes and in the kidney. Sinusoidal membrane transporters MRP1, MRP3, MRP4, 
and MRP6 extrude some drug metabolites (in most cases) or intact drugs back to the 
blood, and present them to bile or renal excretion. On the other hand, canicular 
membrane transporters P-gp, MRP2, and BCRP excrete their substrates directly into bile. 
P-gp is mainly responsible for cationic drugs or metabolites, while MRP2 and BCRP are 
for anionic drugs or metabolites [59]. However, there are also some controversies on the 
importance of MRP2 and BCRP, since it is difficult to differentiate their contribution 
from OATPs. ABC transporters are also located at both the apical and basolateral 
membrane of the renal epithelial cells. P-gp, MRP2, and MRP4 are expressed at the 
proximal tubular basolateral membrane facilitating the excretion of compounds into the 
urine. It seems that P-gp is responsible for excretion of digoxin and some hydrophobic 
cationic drugs, while MRP2 and MRP4 are for anionic drugs or metabolites. MRP1 is 
expressed at the apical cell membrane of distal tubules and collecting ducts. It may be 
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part of a mechanism to prevent drug accumulation (which is toxic to nephron) after water 
re-absorption in that area. 
 
 
1.2.3. Role of ABC transporter on drug resistance  
 
Resistance to chemotherapy is one of the major hindrances to the current 
multimodal cancer treatment paradigms. The resistance can be either a result of changes 
in drug’s ADME at a non-cellular level or the consequence of certain mechanisms within 
tumor cancer cells [74]. As implied by the names of their well-known members (e.g., 
Breast Cancer Resistance Protein, Multidrug Resistance Proteins, as well as the gene 
name of P-gp, Multidrug Resistance gene 1), ABC transporters are involved in drug 
resistance in cancers.  
 
As mentioned in the previous section, some ABC transporters affect ADME of 
chemotherapeutic agents. Therefore, induction of these transporters by the 
chemotherapeutic agent itself or other co-administrated drugs can cause resistance to that 
agent at the non-cellular level. This can work together with other drug resistance 
mechanisms at this level, e.g., drug metabolism enzymes induction in drug-handling 
organs as well as poor vascularization and acidic pH in solid tumors [75, 76]. 
 
Cellular drug resistance can be further stratified into two types: the resistance to a 
class of drugs with a similar mechanism of action, and the resistance to various drugs 
with different structures and targets [75]. The former type of resistance obviously results 
from changes in drug targets, while the latter type, so-called multiple drug resistance 
(MDR), has been a topic of much discussion.  
 
Multiple mechanisms have been proposed for MDR, including reduced sensitivity 
to apoptosis and existence of cancer stem cells, as well as high levels of expressions of 
drug metabolism enzymes (such as GST) and ABC transporters in cancer cells [74, 76]. 
MDR caused by ABC transporters is called “transport MDR” or “classical MDR” while 
MDR by other mechanisms is referred as “atypical MDR” or “non-classical MDR” [74, 
76]. 
 
All 10 aforementioned ABC transporters that are important for ADME plus 3 
additional members (MRP7, MRP8, and ABCA2) have been shown to cause drug 
resistance in cell lines in vitro [77, 78]. In many different cancer tissues from both 
drug-naïve and treated patients, various ABC transporters frequently can be detected 
[79]. However, it is more challenging to get a clear picture of their significance in clinical 
MDR. In order to discern the contribution of ABC transporters from other factors, 
correlation analysis between poor chemotherapy outcome and expression of ABC 
transporters in a large cohort of cancer patients is a necessity. Another reason that makes 
the consensus on clinical relevance of some transporters hard to achieve is the large 




Currently, most studies on the relationship between ABC transporters and clinical 
MDR are focused on P-gp, MRP1, and BCRP, which are also the most extensively 
studied ones in drug ADME. Correlation between P-gp expression and prognosis of 
chemotherapy in breast cancer, sarcoma, and acute myelogenous leukemia (AML) are 
well established [80]. However, the results of clinical trials using specific P-gp inhibitors 
are not very promising [81]. 
 
The expression level of MRP1 does not correlate with the clinical MDR of AML. 
Its significance on the chemotherapy outcome of chronic lymphocytic and promyelocytic 
leukemia, non-small cell lung cancer (NSCLC), and breast cancer has been a point of 
controversy [80]. There are conflicting data regarding the role of BCRP in clinical MDR 
in leukemia [53, 80, 81]. No or little clinical relevance of BCRP expression was found in 
breast cancer, ovarian cancer, and locally advanced bladder cancer. Correlation between 
BCRP expression and adverse prognosis of lung cancer, esophageal cancers, and some 
lymphomas has been reported [82]. 
 
Recently, the cancer stem cells paradigm has been incorporated into the drug 
resistance concept. Cancer stem cells are drug-resistant pluripotent cells expressing high 
levels of ABC transporters, especially BCRP. This subpopulation can survive 
chemotherapy when the other committed non-resistant cancer cells in the original tumor 
mass are killed and therefore serve as an unrestricted reservoir for drug resistant tumor 
relapse [80, 83]. Thus, some conclusions on the relevance of BCRP in clinical MDR need 
to be re-evaluated, since BCRP expression in cancer stem cells was not examined in 
many previous solid tumor studies [82]. Some researchers have proposed that the failure 




1.2.4. Mechanism of action of ABC transporters  
 
Current understanding of the mechanism of action of ABC transporters is briefly 
summarized below (Figure 1-5) [50, 51, 85-90]. As mentioned before, TMDs of ABC 
transporters bind to drug substrates, while NBDs bind to ATP. Binding of substrate to the 
TMD stimulates the ATPase activity. ATPase facilitates ATP hydrolysis and releasing of 
inorganic phosphate (Pi) and adenosine diphosphate (ADP). ATP hydrolysis provides the 
energy to cause a conformational change at the TMDs. TMDs will change from 
inward-facing conformation (facing the inside) to outward-facing conformation (facing 
the outside) and release substrate to the extracellular space. Experimental data supported 
that two ATP hydrolysis events are needed to transport one drug molecule. These two 
events do not happen simultaneously. The first ATP hydrolysis is needed to transport the 
substrate and the second ATP hydrolysis is needed to “reset” the transporter from 
outward facing back to forward facing so that the transporter can bind substrate again 
[91]. Formation of a homodimer or heterodimer is a prerequisite for functionality of 
half-transporters such as BCRP [50, 58, 92]. 
 






Figure 1-5.  Mechanism of action of a typical ABC transporter 
 
ATP dependent closure/dimerization of cytosolic NBDs provides the power stroke that 
pulls the TMDs from an inward- to outward facing conformation. Both exporters and 
importers probably use the same basic mechanism but shift which state binds the 
transport substrate (red) with high affinity. Most eukaryotic ABC transporters are 
heterodimers, with 2 homologous but nonequivalent halves (green and blue). 
 
Source: Reprinted with permission. Procko, E., et al., The mechanism of ABC 
transporters: general lessons from structural and functional studies of an antigenic 
peptide transporter. The FASEB Journal, 2009. 23(5): p. 1287-302.  
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detect the activity of ABC transporters to determine substrates and inhibitors of ABC 
transporters. The ATPase assay contains two modes, activation mode and inhibition 
mode. Under activation mode, ABC transporter substrates bind to the TMD and stimulate 
ATPase activity, which further hydrolyzes ATP and releases Pi, which can be detected by 
a colorimetric reaction and is proportional to the ATPase activity. Increased Pi release 
suggests that a compound is a substrate of ABC transporters. Under inhibition mode, Pi 
release is detected in the presence of a known ABC transporter substrate with or without 
a test compound. If the test compound is an inhibitor of the transporter or slowly 




1.2.5. Effect of p53 on ABC transporters  
 
Conflicting data suggested that p53 may also regulate the expression of ABC 
transporters [95, 96]. In 1992, Chin et al. first reported that the MDR1 promoter was 
repressed by wild-type p53 [97]. Later, Stauss et al. reported that the MDR1 downstream 
promoter contains a wild-type p53-binding site [98]. Unlike wild-type p53, mutant p53 
was found to activate the MDR1 promoter [97]. Similarly, Zastawny et al. also reported 
that wild-type p53 represses MDR1 promoter activity, and mutant p53 enhances MDR1 
promoter activity [99]. Further study showed the overlapping region on the MDR1 
promoter for mutant p53 transactivation and for basal promoter activity [100]. A study by 
Sampath et al. suggested while mutant p53 requires an Ets-1 transcriptional factor 
binding site to regulate MDR1 promoter transcriptionally, wild-type p53 does not interact 
with Ets-1 [101]. The increased MDR1 expression could be caused by both a loss of p53 
repression on MDR1 promoter and an increased transactivation of MDR1 through a “gain 
of function” of mutant p53 [102]. However, the role of p53 in regulating MDR1 is still 
controversial [95, 102]. Transfection of wild-type p53 expression had been reported to 
stimulate MDR1 promoter in p53 negative cell lines [103] or show no (or marginal) 
change in MDR1 gene expression and function [104, 105]. 
 
In addition to MDR1, wild-type p53 has been reported to suppress MRP1 reporter 
activity [106]. Unlike MDR1, mutant p53 did not up-regulate MRP1 [101, 106]. Data 
about regulation of MRP1 by p53 is also conflicting. Wild-type p53 enhanced MRP 
expression and activity instead of suppressing MRP1 expression in three of the five cell 
lines, and no change was observed in other two of the five cell lines [96]. Recently, Wang 
et al. reported that wild-type, but not mutant p53, can reduce the expression of BCRP in 
MCF-7 cells [107].  
 
Regulation of ABC transporter expression by p53 can have a functional effect on 
drug resistance. For example, wild-type p53 inactivation (introduced by expressing 
dominant negative mutant p53) increased the expression of MDR1. This leads to 
decreased uptake and increased resistance to vinblastine [102]. Increased vincristine 
sensitivity after changing the cells from expressing dominate negative mutant p53 to 





1.2.6. Evaluation of transporter mediated drug-drug interaction
 
Because of the important roles of transporters on drug disposition, inhibition or 
activation of ABC transporter(s) may alter the PK of a compound that is substrate(s) of 
ABC transporter(s). For example, oral co-administration of P-gp inhibitor clarithromycin 
can lead to a 64% increase of AUC of P-gp substrate digoxin, which explains the clinical 
cases of clarithromycin-induced digoxin toxicity [108]. P-gp inhibitor dronedarone 
resulted in a 157% increase of digoxin AUC [47]. BCRP and P-gp inhibitor GF120918 
resulted in a 143% increase of oral topotecan AUC [47]. Therefore, in vitro and 
sometimes in vivo follow-up studies are needed to understand transporter-mediated 
drug-drug interaction for avoiding serious adverse events.  
 
In 2006, the Food and Drug Administration (FDA) published guidance for 
studying transporter-based drug-drug interactions. A decision tree regarding 
P-gp-mediated drug-drug interaction was included in the guidance [47]. In 2010, the 
International Transporter Consortium further broadened the decision tree (Figure 1-6) 
[47]. Approaches to answer important questions were addressed for both ABC 
transporters (P-gp and BCRP) and SLC transporters (organic cation transporter (OCT) 
and the organic anion transporter (OAT)) [47]. These questions include, for example, 
which transporters are important for drug absorption and disposition, what in vitro 
methods are recommended to evaluate drug-transporter interaction, and what are the 
criteria for conducting clinical studies based on in vitro data. 
 
For P-gp and BCRP, the bidirectional transport assay using polarized monolayer 
cells is one of the important preferred functional studies to identify if a compound is a 
substrate and/or inhibitor of P-gp. Caco-2 cells are derived from human epithelial 
colorectal adenocarcinoma cells. When cultured under specific conditions, Caco-2 cells 
become differentiated, polarized, and functionally resemble the morphology, polarity, 
and expression patterns of the transporters and enzymes of the small intestine [109]. 
Caco-2 cells have been widely used as an in vitro model to evaluate intestinal drug 
absorption and efflux. Transporter transfected Madin-Darby canine kidney epithelial 
(MDCK) cells or porcine kidney epithelial cells (LLCPK1) cells are also routinely used 
in bidirectional transport assay. Similar to Caco-2 cells, these cells can also polarize and 
form a monolayer. Because P-gp and BCRP are expressed at the apical side of the 
polarized cells [109], B to A transport represents the passive diffusion and the efflux of a 
compound, and A to B transport represents the passive diffusion and the uptake of a 
compound. Therefore, it is important to look at both A to B and B to A direction for 
evaluating P-gp and BCRP efflux in the system. When interpreting data from these 
systems, one must consider that multiple endogenous drug transporters are expressed in 
Caco-2 (P-gp, BCRP, MRP1-6, ABCA1, ABCG1, HPT1 and many SLC family uptake 
transporters) [110], MDCK II (P-gp, MRP1, MRP2, and MRP5) [111, 112], and LLC-PK 
1 (P-gp, MRP1 and MRP2) [113].  
 
A decision tree for P-gp or BCRP substrate interactions is listed in Figure 1-6 
[47]. An efflux ratio less than 2 indicates poor or non-P-gp (or non-BCRP) substrate. For 
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Figure 1-6.  Decision trees for studying transporter-based drug-drug interactions 
A. Decision tree for P-gp or BCRP substrate interaction. A new molecular entity (NME) 
is considered to be a potential P-gp or BCRP substrate if the efflux ratio — basal to 
apical (B-A) to apical to basal (A-B) — is  2 in an epithelia cell system that expresses 
one or both transporters (see (a) in the figure). A net flux ratio cut-off higher than 2 or a 
relative ratio to positive controls may be used to avoid false positives if a ratio of 2 is 
deemed non-discriminative as supported by prior experience with the cell system used. 
Additional corroboration that an NME may be a P-gp or BCRP substrate can be achieved 
with the use of inhibitors. Reduction of the flux ratio by the P-gp (or BCRP) inhibitors 
should be greater than 50% (see (b) in the figure). If the flux ratio is not reduced by P-gp 
(or BCRP) inhibitors, then other efflux transporters may be responsible for the observed 
net flux (see (d) in the figure).  
 
B. Decision tree for transporter inhibitor interaction. [I]1 is the steady-state total Cmax at 
the highest clinical dose, and [I]2 is the theoretical maximal gastrointestinal drug 
concentration after oral formulation at the highest clinical dose in a volume of 250 ml.  
 
Source: Adapted with permission. Giacomini, K.M., et al., Membrane transporters in 
















compounds with efflux ratio  2, inhibitor (s) will be used. If the efflux ratio reduction is 
larger than 50 % or the efflux ratio close to 1 can be achieved after adding P-gp (or 
BCRP) inhibitor(s) at effective concentration, the compound is probably a substrate of 
P-gp (or BCRP). Otherwise, other efflux transporters may be responsible for the high 
efflux ratio. If an in vitro study suggested that a compound is a substrate of P-gp or 
BCRP, an in vivo drug-drug interaction study may be needed, depending on the property 
of a compound. For a drug that falls into Biopharmaceutics Classification System (BCS) 
Class I (high solubility, high permeability) or Biopharmaceutics Drug Disposition 
Classification System (BDDCS) Class I (high solubility, extensive metabolism), even if it 
could be P-gp substrate in vitro (for example, verapamil), its bioavailability is not likely 
to be affected by P-gp modulators [114]. If disposition in kidney, brain, and tumor is not 
important for that drug, then no in vivo studies on drug-drug interaction are necessary 
[114].  
 
 If a compound reduced the efflux ratio of P-gp (or BCRP) in bi-directional 
transport assay, this compound might be a potential P-gp (or BCRP) inhibitor in vivo. The 
International Transporter Consortium recommended [I]1/IC50  0.1 or [I]2/IC50 > 10 as 
cut-off values for further in vivo drug interaction studies (Figure 1-6B) [47]. IC50 is the in 
vitro IC50, [I]1 is the steady-state unbound Cmax at the highest clinical dose, and [I]2 is 
the theoretical maximal gastrointestinal drug concentration after oral formulation at the 
highest clinical dose in a volume of 250 ml. If [I]1/IC50  0.1 or [I]2/IC50 > 10 occur, an in 
vivo drug interaction study with P-gp or BCRP substrate is recommended. One possible 
substrate for an in vivo P-gp-mediated drug interaction study is digoxin, and possible 
substrates for an in vivo BCRP-mediated drug interaction study are sulphasalazine, 
rosuvastatin, pitavastatin, ciproflozacin, and dipyridamole. 
 
 




1.3.1. Introduction of PBPK model 
 
 
1.3.1.1. Classical and PBPK model. Disposition of a drug by the body is a 
complex process. A compound can be administered by various routes such as oral, 
intravenous, subcutaneous, intramuscular, or subconjunctival injection. Through various 
mechanisms of absorption, the drug is absorbed and then distributed to the tissues by the 
body fluids (e.g., blood, lymphatic system, CSF). The drug can be metabolized in the 
liver and/or other tissues to other compound(s) and/or eliminated unchanged through bile 
or the kidney. Protein binding in the plasma and different tissues can be different due to 
various protein contents. As discussed earlier, efflux and uptake transporters expressed 
throughout the body can impact the ADME process. In the same tissue, drug 
concentrations in the vascular, extracellular, and intracellular compartments can be 
different. Due to the complexity of this process, drug concentrations in the blood and in 
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different parts of the body can be quite variable. Thus drug concentrations in the plasma 
do not always reflect target tissue concentrations. 
 
An appropriate pharmacokinetic model that adequately describes and reasonably 
predicts the time-dependent drug concentrations in the body is critical in both preclinical 
and clinical drug development. Currently, two broad approaches to pharmacokinetic 
analysis are classical (sometimes called empirical or conventional) and PBPK models, 
although the two approaches do share similar features. 
 
 The classical pharmacokinetic model focuses mainly on the drug concentrations 
in blood (whole blood, plasma, or serum) or other easily accessible body fluids (urine, 
feces, CSF, or breast milk). It generalizes the complex drug distribution process into 
multiple theoretical compartments. An example of classic PK model structure is provided 
in Figure 1-7. Compartments in classical PK models do not represent real organ 
compartments and usually lack mechanistic insight. This limits their application in certain 
areas of drug discovery and development such as predicting human systemic and target 
tissue drug concentrations based on in vitro data or animal PK data, and predicting 
drug-drug interactions. 
 
PBPK models, on the other hand, are more complex models that map the drug PK 
process onto physiologically realistic compartment structures. A typical structure of a 
PBPK model is given in Figure 1-8 [115]. In such a model, the body is usually modeled 
as a closed circulatory system consisting of tissues that are important for drug absorption, 
distribution, metabolism, elimination, or any other tissues that are of interest. 
Compartments that represent real tissues are connected by blood flow. In general, 
tissue-specific arterial blood flow serves as model input into the tissues and comes out of 
the tissues as venous blood, thus serving as model output, with some exceptions. For 
splanchnic organs such as stomach, intestine, spleen and pancreas, venous blood flows 
into the liver through the portal system. For the lung, the pooled venous blood flows in 
the lung and arterial blood flows out of the lung. In contrast to the classic PK model, the 
physiologically-based nature of the PBPK modeling allows us to address mechanistic 
questions with regard to the PK as well as extrapolating knowledge obtained from one 
species to another, including human. 
 
However, the distinction between the classic and PBPK model is not always clear. 
As Nestorov mentioned in his reviews, it is impossible and unnecessary to define 
formally what a PBPK model is or to specify a clear distinction between the classic and 
PBPK model [116, 117]. The classic model (especially mechanistic PK model) contains 
more and more physiological information (e.g., including body weight in the allometric 
scaling, using bile empty time for modeling enterohepatic circulation). And the PBPK 
model usually incorporates classic PK model components. For example, PBPK modeling 
software PK-sim® incorporates the animal clearance value from classic PK model into 
the PBPK model to predict concentration time profile both in animal and in human. Also, 
one important step for establishing the whole body PBPK model is to generate PK model 
in the plasma using classic PK modeling. To distinguish between a predominantly 















Figure 1-8.  Typical structure of a whole-body PBPK model 
 
Q refers to blood flow: to the lungs (Qpul), the heart (Qca), the kidneys (Qre), the bones 
(Qbo), the muscles (Qmu), the spleen (Qsp), the liver (Qha), the hepatic vein (Qhv), the 
gut (Qgu), the fat (Qfa), the skin (Qsk), and the thymus (Qth).  
 
Source: Adapted with permission. Kawai, R., et al., Physiologically based 
pharmacokinetics of cyclosporine A: extension to tissue distribution kinetics in rats and 
scale-up to human. The Journal of Pharmacology and Experimental Therapeutics, 1998. 




structure. As mentioned in a review by Nestorov, if the model structure precedes the 
analysis of the compound specific data, and predominantly represents actual tissue or 
organ spaces, then it can be classified as a PBPK model [117]. It should be mentioned 
that both the classical PK model and the PBPK model belong to the compartment PK 
model hierarchy because both models classify the body into a number of subunits called 
“compartments” [117, 118]. 
 
 
1.3.1.2. PBPK application area. Due to the advances in computing power, PBPK 
models have been increasingly used in recent years [119]. The majority of all PBPK 
related publications (60%) deal with issues pertaining to risk assessment of 
environmental chemicals [120]. Because the PBPK model is more mechanistically, 
anatomically, and physiologically relevant than the classic compartment modeling, the 
established PBPK model from animal study can be used to extrapolate to humans.  
 
In the drug discovery and development area, there is a particular interest to use 
the PBPK model for estimating the human PK of drug candidates from in silico, in vitro, 
or in vivo animal PK data and to select the most promising compounds for further 
development. Methods for predicting human PK are quite variable, and many methods 
are under evaluation. For example, detailed scaling methods can be found in recently 
published papers from the Pharmaceutical Research and Manufacturers of America 
(PhRMA) group, including 24, 29, and 66 methods for predicting human volume of 
distribution, human clearance and oral area under the curve, respectively [121-125], 
based on in vitro and animal PK data. PBPK model has also been used for special 
population—such as pediatrics [126-134], elderly patients [135, 136], pregnant [137-139] 
and lactating [140, 141] individuals, and for patients with organ impairments [142]. It has 
been applied to predict human drug-drug interaction [130, 143-151], inter-individual 
variability [120], and the effect of genetics [152-154]. In addition to small molecules, the 
applications of the PBPK model have also been extended to large molecules [155-163] 
and nano-particles [164-167].  
 
 
1.3.1.3. PBPK model software. Software is a critical tool for establishing PBPK 
models and performing simulations. There are a number of commercial software products 
developed for building PBPK models, including Simcyp (Simcyp Ltd., Sheffield, UK), 
GastroPlusTM (Simulations Plus Inc, Lancaster, CA) and PK-Sim® (Bayer Technology 
Services, Leverkusen Germany). These products usually do not require code writing and 
are capable of performing complex IVIVE simulation, DDI prediction, and extrapolating 
PK parameters from adults to pediatric population without in vivo experiment data. 
Software such as SAMM II, NONMEM, ADAPT, and Phoenix (WinNonlin 6) can be 
used for both conventional PK and PBPK modeling. Different software requires different 
coding. In some cases, such as in SAAMII and Phoenix WinNonlin 6, writing code may 






1.3.2. Basic concepts of PBPK modeling 
 
 
1.3.2.1. Major components of PBPK model. Inputs to PBPK models comprise 
drug-independent and drug-dependent information. Organ mass or volume, blood flow, 
tissue composition, and the anatomical arrangement of the tissues and organs of the body 
are drug-independent components. Drug-dependent information includes partition 
coefficients, protein binding, PK properties, membrane permeability, enzymatic stability, 
and transporter-drug relationships. Since drug-independent components and many of the 
drug-dependent components are not required in the classical PK model, it is believed that 
the PBPK model contains richer informational content.  
Besides data collection, the general procedure for developing PBPK models 
consists of three major steps [116]: 1) specification of whole body structure and the tissue 
structure, 2) writing differential equations, and 3) estimating parameters.  
 
 
1.3.2.2. Specification of whole body structure and tissue structure 
 
 
1.3.2.2.1. Specification of whole body structure. To establish a PBPK model for a 
specific compound, the whole body structure needs to be built to meet specific study 
purposes. It is important to decide which tissues/organs to include in the model. On one 
hand, the PBPK model should contain a large amount/number of tissues/organ that are 
important for drug ADME and tissues of special interest. On the other hand, for practical 
reasons, too many tissue/organ compartments not only increase the need for a lot of 
experimental data and literature information but also increase the difficulty of the 
mathematical calculations. Although currently there is no definite rule for selection of the 
tissues to be included, in general “core tissues” such as blood, liver, kidney, adipose, and 
tissues of interest are included in the model [116]. All the rest of the tissues can be 
lumped into “rapid equilibrating” or “slow equilibrating” compartments. When both a 
parental drug and its metabolite(s) are studied, separate PBPK models should be 
developed for both the drug and the metabolite(s). The models are then linked through 
the metabolism compartment (usually liver) with one part of the parent drug elimination 
output serving as input for the metabolite(s) [168, 169].
 
 
1.3.2.2.2. Specification of tissue structure. After a whole body structure is 
defined, the next step is to specify the structure of a specific tissue. In most cases, a 
simple perfusion limited model is used for the tissues (Figure 1-9A) [168]. The 
underlying assumption is that the drug distributes instantly in the tissues and there is no 
concentration gradient existing in the tissues. Although making this assumption 
oversimplifies the real situation, it has the major advantage of reducing the model 
complexity. When permeability limits the distribution of a drug within a tissue, a 
diffusion-limited model can be applied (Figure 1-9B) [168]. One tissue compartment can 
be divided further into two or three compartments. For a two compartment model in a 
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Figure 1-9.  Structures and equations for individual organ models 
A. Perfusion-limited model for non-eliminating organs. VT is the total volume of organ T; 
QT is the blood flow to the organ; CT is the concentration of the drug in the organ; RT is 
the partition coefficient; CArt is the concentration of drug in arterial blood; CT, Ven is the 
venous effluent drug concentration (CT Ven = CT/RT). In this model, the measured tissue 
concentration is CT.  
 
B. Diffusion-limited model for non-eliminating organs. CT,V and VT,V represent the drug 
concentration and volume for the organ vascular space; CT,EV and VT,EV represent the 
corresponding terms for the extra-vascular space; kV,EV and kEV,V represent the drug 
transport rates between the vascular and extra-vascular spaces; fub is the fraction of 
unbound drug in the vascular space. In this model, the measured tissue concentration is 
CT,EV.  
 
C. Perfusion-limited model for eliminating organ. CLintT represents the intrinsic clearance 
of the drug. 
 
D. Diffusion-limited model for eliminating organs. CLintT represents the intrinsic 
clearance of the drug. 
 
Source: Adapted with permission. Xu, L., et al., Physiologically-based pharmacokinetics 
and molecular pharmacodynamics of 17-(allylamino)-17-demethoxygeldanamycin and its 
active metabolite in tumor-bearing mice. Journal of Pharmacokinetics and 





certain tissue, if the rate limiting step is assumed to happen in the capillary membrane, 
then the two compartments represent the vascular and extra-vascular compartments; if the 
rate limiting step is assumed to happen at the cell membrane, then the two compartments 
represent intra- and extra-cellular compartments. For the three compartment model in a 
certain tissue, it is assumed that both the capillary and cell membrane are rate-limiting 
steps for the drug. And the three compartments represent vascular, interstitial, and 
cellular compartments [116]. For eliminating organs, an eliminating function component 
is added to the model structures (Figure 1-9C, D) [168]. In reality, a whole body PBPK 
model can be composed of both perfusion- and diffusion-limited tissues. For example, the 
whole body PBPK model developed for 17-(allylamino)-17-demethoxygeldanamycin 
(17-AAG) contains both perfusion-limited organs (lung, brain, heart, spleen, kidney, and 
muscle) and diffusion-limited tissue (tumor) [168]. Whole body PBPK model developed 
for topotecan contains both perfusion-limited organs (lung, heart, muscle, adipose, skin, 
brain, liver, spleen, and gut) and diffusion-limited organs (kidney and testes) [170].  
 
 
1.3.2.3. Writing differential equations. As in classic PK modeling, PBPK 
modeling equations are written following the mass balance equation. The difference is 
that the structure and components of the model represent real physiology. Examples of 
the equations are listed in Figure 1-9 [168]. During model development process, 
equations may be modified. 
 
 
 1.3.2.4. Estimating parameters. In order to estimate parameters, in addition to 
experimental data, physiological and anatomical data should be collected for modeling. 
However, obtaining reliable physiological parameters is not an easy task. Inaccurate 
physiological parameters used in the model will affect value of the final model. Among 
all the parameters, sensitivity analysis showed that blood flow is the most influential 
parameter [171]. Since various conditions such as anesthesia and stress can alter blood 
flow, using physiological data that are obtained under these conditions may bias the 
modeling results. 
 
 Because of the complexity of the PBPK model, PBPK parameter estimation 
usually is conducted from the open loop to closed loop (Figure 1-10). Blood 
concentration is first modeled using the empirical approach. The established blood PK 
model from the empirical approach is then used as a forcing function to each individual 
tissue. In this step, information such as blood flow, organ weight, and partition 
coefficient are used or estimated. Since individual tissues are still isolated, the model at 
this stage is open loop. Then the PBPK model is modified to a closed circulating system. 
Due to the computational challenges in modeling all the PBPK parameters at the same 











Figure 1-10.  Schematic structure of open loop and closed loop 
 
In the open loop form, separate PBPK models were established for individual organs. 
Later in the closed loop form, all the modeled organs are linked together to form an 
anatomically integrated PBPK model. Q refers to blood flow to the lung (QL), organ 1 





1.3.3. Applications of PBPK model in drug discovery and development  
 
 
1.3.3.1. Predicting human ADME and whole plasma PK profile using PBPK 
model. In early drug development stages, the measurements or simulation of 
drug-specific data—such as molecular weight, Log P (or Log D), pKa, plasma protein 
binding, and in vitro hepatic intrinsic clearance—can be incorporated into the PBPK 
model to predict animal and human ADME and facilitate candidate selection. Full plasma 
concentration-time profiles following different dosing schedules can be predicted by the 
PBPK models. For example, using the PBPK model, Jones et al. from F. Hoffmann-La 
Roche reported better prediction of human plasma concentration compared to commonly 
used allometric scaling (Dedrick approach) for compounds with distinct physicochemical 
and pharmacokinetic properties [119, 172]. In addition to the report from Jones et al., 
various approaches had been reported to predict ADME [119, 125, 173-180]. These 
prediction methods are generally complex, and the new trend and preferred approach is to 
perform prediction using commercially available PBPK software such as Simcyp, 
Gastroplus, and PK-Sim (mentioned in section 1.3.1.3). 
 
Figure 1-11 represents the general scheme for predicting human PK data using 
this approach. Human concentration-time profiles under various dosing schedules can be 
generated when drug-specific data are provided. This can greatly simplify the ADME 
prediction process. In addition, animal PK data can be incorporated into the PBPK model 
to generate a human PK profile or to validate the IVIVE prediction. In this case, a PK 
parameter (such as clearance) estimated using the classic PK model is incorporated into 
the PBPK model to obtain a better prediction. More studies are needed to validate the 
predictive ability of the software. And more improvement is needed, especially for 




 1.3.3.2. Drug distribution in target tissues and tumors. PBPK models have 
been used to understand and predict target tissue and tumor concentrations. In the 
oncology area, a PubMed search (09/12/2011) using “physiologically based 
pharmacokinetic model cancer” or “physiologically based pharmacokinetic model tumor” 
returned 153 papers. PBPK models had been used for antibody [155-158, 160-163, 
181-183], liposomal [184], imaging agents [185-187], radioimmunodetection and 
radioimmunotherapy [188, 189], and small molecules such as topotecan [170], docetaxel 
[190, 191], gefitinib [192-194], moxifloxacin [195], capecitabine [196, 197], 
temozolomide [198, 199], genistein [200, 201], doxorubicin [136], 17-AAG [168], and 
methotrexate [202, 203]. General methods and principles of model development have 
been discussed in 1.3.1 and 1.3.2.  
 
Partition coefficient is an important parameter in the PBPK model. Multiple 
methods for obtaining the partition coefficient values were applied as follows: 1. 
Estimation using PBPK model. 2. Estimation using non-compartmental modeling. Shah 






Figure 1-11.  General schemes to incorporate drug dependent parameters into a 
PBPK model 
 
Peff, jejunum permeability; AUC, area under the concentration vs. time curve; B/P, blood 
to plasma ratio; Cmax, maximum concentration; CL, clearance; CLint, intrinsic 
clearance; CLr, renal clearance; DDI, drug–drug interaction; EC50 or IC50, concentration 
causing half of the maximal effect of induction or inhibition; Emax or Imax, maximum 
effect of induction or inhibition; F, bioavailability; Fa, fraction absorbed; Fg, 
bioavailability in the gut; Fh, bioavailability in the liver; fu,p, unbound fraction in 
plasma; , Hill coefficient; Jmax, maximum rate of transporter-mediated efflux/uptake; 
Ka, first-order absorption rate constant; Kd, dissociation constant of drug–protein 
complex; Ki, reversible inhibition constant; KI, apparent inactivation constant, 
concentration causing half of the maximal inactivation; kinact, apparent maximum 
inactivation rate constant; Km, Michaelis–Menten constant, substrate concentration 
causing half of the maximal reaction or transport; Kp, tissue-to-plasma partition 
coefficient; LogP, logarithm of the octanol–water partition coefficient; MOA, mechanism 
of action; PD, pharmacodynamics; PK, pharmacokinetics; PopPK, population 
pharmacokinetics; V, volume of distribution; Vmax, maximum rate of metabolite 
formation. 
 
Source: Reprinted with permission. Zhao, P., et al., Applications of physiologically based 
pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clinical 




plasma partition coefficient for each tissue was first estimated using the ratio of AUC 
(estimated from non-compartmental modeling) for the tissue to the ratio in plasma. These 
values were then fixed and applied to the whole body PBPK model. 3. In vitro 
measurements. Bradshaw-Pierce et al. reported a PBPK model for docetaxel [204]. The 
PBPK model for docetaxel was developed incorporating specific binding of docetaxel to 
intracellular components, liver metabolism, biliary elimination, and fecal and urinary 
excretion. Tissue/blood partition coefficients were determined in vitro [204, 205]. 
Docetaxel was incubated with minced tissue at 37ºC with gentle shaking for 24 h. 
Samples were centrifuged to separate tissue from saline. Docetaxel concentration was 
measured in both the saline and tissue layer. The partition coefficient was determined by 
the ratio of docetaxel concentrations in the tissue layer to the saline layer. These values 
were fixed and applied to the whole body PBPK model. 4. Calculation. Sung et al. 
reported a PBPKPD model for UTF (5-FU, tegafur, and uracil) [206]. Partition 
coefficients for tissues were calculated based on the n-octanol-water partition coefficient 
developed by Poulin and Theil [207, 208]. The estimation of partition coefficient for 
tumor was adjusted during model development. Once a PBPK model is established, 
scaling the concentration from one species to another can be done by changing the 
physiological information but keeping the model structure and assuming identical 
partition coefficients between species [168, 192, 198].  
 
 
1.3.3.3. Predicting the risk for drug-drug interactions. Drug-drug interactions 
can cause serious toxicities or loss of efficacy. Due to the fact that many drugs are 
substrates and/or inhibitors of various drug metabolizing enzymes and efflux transporters, 
the degree of drug-drug interaction is a concern when drugs are used in combination. To 
understand the potential for a drug-drug interaction for a certain drug, evaluations are 
usually conducted in clinical trials or in preclinical settings. Now, by combining the 
physiological information and the drug metabolism enzyme/transporter inhibition/or 
induction knowledge obtained in vitro experimentally, the PBPK model can be used to 
simulate and predict drug-drug interaction in humans. Multiple PBPK model applications 
for predicting drug-drug interactions have been reported [130, 143-150]. For example, 
Johnson et al. built a pediatric PBPK (P-PBPK) model to predict drug concentration-time 
profiles and drug-drug interactions in children [130]. Using Simcyp Pediatric ADME 
Simulator, concentration time profile was simulated for a 2-year-old child prescribed with 
CYP3A4 inducer, CYP3A4 inhibitor, and substrates with complex dosing schedules.  
The FDA reported example cases of using a PBPK model during investigational 
new drugs (INDs) and new drug applications (NDAs) reviews between July 2008 and 
June 2010 [149]. In these cases, the PBPK approach had been used to address multiple 
specific regulatory questions, such as whether a drug-drug interaction study can be ruled 
out even though the ratio of in vivo inhibitor concentration I (maximum plasma 
concentration at the highest proposed dose) to the in vitro inhibition constant (Ki) (I/Ki) 
is > 0.1. The software used in the study included GetData 2.24 (for digitizing 
concentration-vs.-time profiles), WinNonlin 5.2, NONMEM (for PK parameter 
estimation), and PBPK simulators (Simcyp, PK-Sim, Gastroplus, and SAAMII). At the 
same time, it should be mentioned that the PBPK model used in this case relies largely on 
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in vitro and in silico data. Some important parameters needed may not be available in 
earlier drug development stage. As the compound progresses to later stage, the PBPK 
model can be refined incorporating the available data.  
 
 
1.3.4. Limitation of PBPK modeling 
 
 So far, in comparison to the classical PK model, the application of the PBPK 
approach is still limited despite significant potential. Developing a PBPK model is 
demanding because of the investment of large amount of time and effort to obtain 
information needed to establish the model. In addition, data required to establish the 
model are not always available. Variations in physiological parameters obtained from the 
literature, our current limited knowledge about the underlying mechanism about drug 
ADME process, and wrong assumptions can all affect the quality of the model. The 
PBPK model is usually structurally complex and much more methodologically and 
computationally challenging compared to the classic PK model. Furthermore, PBPK 
model is not as mature as conventional PK model. 
 
Despite all of the limitations of the PBPK model mentioned above, the PBPK area 
is developing rapidly. The knowledge and methods for building the model are 
continuously accumulating and improving. The PBPK model breaks the limit of 
conventional PK by building a model and understanding the PK process based on the real 
physiological and anatomical system, and by incorporating rich knowledge learned over 
the years about effect of drug dependent and independent factors on PK. In the drug 
discovery and development area, pharmaceutical companies are acquiring PBPK 
modeling software for predicting human PK based on in vitro and/or animal in vivo PK 
data. Also, the regulatory authority has started appreciating the benefit of the PBPK 
model and applying the PBPK model to address drug regulatory review questions. At 
last, but not least, the PBPK model will be applied with increased frequency in the 
toxicology and oncology areas where understanding target tissue or tumor concentration 





Reactivating the p53 pathway is regarded as an appealing nongenotoxic approach 
for treating tumors with wild-type p53. Unlike adult cancers, pediatric malignancies 
usually retain a high percentage of wild-type p53 status at diagnosis. Using 
neuroblastoma as an example, 98% of neuroblastoma tumors retain wild-type p53 at 
diagnosis [209, 210]. Even in relapse neuroblastoma, a majority of the tumors are still 
p53 wild-type [211]. Nutlin-3a is a small molecule inhibitor that targets the 
MDM2/MDMX-p53 interaction. It is currently under pre-clinical investigation in a 
variety of solid tumor and leukemia models, and has shown promising in vitro and in vivo 
activities. Like most other anticancer drugs, it is most likely that nutlin-3 will be used in 
combination. Studies have suggested synergistic effects when nutlin-3 and other 
chemotherapeutic drugs were co-administered, independent of p53 status, by enhancing 
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the ability of anticancer drugs to activate apoptosis or by reversing P-gp-mediated drug 
resistance. ABC transporters play important roles in drug resistance and ADME 
processes. The effect of nutlin-3a on BCRP had not been reported before.  
 
Understanding the pharmacokinetics of a compound is critical in preclinical drug 
development. An understanding of the systemic disposition of nutlin-3a, as well as the 
distribution to target tissue or tumor sites, will provide a rational basis for the selection of 
dosage regimens for preclinical models. To date, the pharmacokinetics of nutlin-3a has 
not been reported. Whole-body PBPK model, which is based on anatomical 
compartments and blood flow, is an excellent tool to describe and predict drug 
concentration not only in blood but also in target tissues. 
 
 
1.5. Specific Aims 
 
 The objective of specific aim 1 was to assess the effect of nutlin-3a on cell 
viability, both as a single agent and in combination with one of the commonly used 
anti-neuroblastoma agents, topotecan.  
 
 The objective of specific aim 2 was to investigate whether nutlin-3a inhibits 
BCRP, thus sensitizing cells to enhanced killing by anti-cancer drugs that are BCRP 
substrates. Based on initial observations, we performed a series of studies to investigate 
the effect of nutlin-3a treatment on BCRP expression and function comprehensively 
[212].  
 
 The objective of specific aim 3 was to perform pharmacokinetic studies and 
develop a PBPK model describing the disposition of nutlin-3a in plasma and tissues, 
including adipose, adrenal gland, bone marrow, brain, liver, lung, intestine, muscle, 
retina, spleen, and vitreous fluid. The PBPK model was used to perform simulations, 
which— in combination with in vitro cell sensitivity data— provided rationale for 
choosing dosing regimens for mouse models of common childhood cancers, including 
retinoblastoma, neuroblastoma, rhabdomyosarcoma, and acute lymphoblastic leukemia 





CHAPTER 2. MDM2 ANTAGONIST NUTLIN-3A SYNERGISTICALLY 





Neuroblastoma [214] is an embryonic malignancy of the sympathetic nervous 
system. It is the second most common extra-cranial solid tumor of childhood [215] and 
the most common cancer of infancy [216]. While other childhood cancers have 
experienced an improved cure rate over the past decades, high risk neuroblastoma is still 
one of the most difficult tumors to treat, with less than 30% long-term survival despite 
aggressive multi-modal therapy including surgery, radiation, high-dose chemotherapy, 
and stem cell transplantation [217]. 
 
To provide a new therapy for neuroblastoma, effective molecular targets should 
be selected. One of the targets that we studied is p53. p53 plays a central role in 
regulating cell cycle arrest, senescence, and apoptosis. The p53 gene is mutated in half of 
all tumors, and in those tumors that retain wild-type p53, p53 function may also be 
suppressed by its negative regulators. As a key negative regulator of p53 [218], oncogene 
MDM2 effectively impairs p53 stability and activity. Strong evidence for the relationship 
between MDM2 and p53 has made inhibition of the MDM2-p53 interaction an attractive 
target for reactivating p53. 
 
One crucial point of neuroblastoma is that 98% of neuroblastoma tumors retain 
wild-type p53 at diagnosis [209, 210]. Even in relapse neuroblastoma, a majority of the 
tumors are still p53 wild-type [211]. Although many mechanisms for inactivation of p53 
pathway had been proposed [211, 219], several studies indicate that the p53 downstream 
pathway is intact in neuroblastoma and can be activated in response to DNA damage 
[220]. These data suggest that regardless of many other unclear possible mechanisms of 
p53 inactivation, p53 downstream pathway is intact, which encouraged us to restore the 
function of p53 by directly stabilizing p53 protein using the MDM2-p53 interaction 
inhibitor to treat neuroblastoma. 
 
The results of preclinical studies have shown that the MDM2 antagonist nutlin-3a 
is a promising agent to reactivate p53. Nutlin-3a has demonstrated anti-tumor efficacy in 
preclinical models of human osteosarcoma, retinoblastoma, and KSHV lymphoma with 
wild-type p53 [17, 24, 25, 39-41]. In neuroblastoma, studies have found that MDM2 
antagonist nutlin-3a is effective both in vitro [36, 221, 222] and in vivo [43].  
 
Several studies suggested that when nutlin-3a was combined with anti-cancer 
agents, synergistic growth inhibition was observed [31, 35, 37]. In neuroblastoma, 
nutlin-3 synergized (or sensitized) neuroblastoma cells to chemotherapeutic agents 
(R)-roscovitine [36], cisplatin [221], etoposide [221], and doxorubicin [223, 224]. So far, 
combining nutlin-3 with topotecan, a commonly used anti-neuroblastoma agent, has not 




In this study, we reported that nutlin-3a synergistically inhibited neuroblastoma 
cell growth with topotecan. To explore a possible mechanism, we studied the effect of 
nutlin-3a on the expression of efflux transporter P-gp. 





Nutlin-3a were synthesized in the Department of Chemical Biology at St. Jude 
Children’s Research Hospital, Memphis, TN, and were solubilized in dimethyl sulfoxide 
(DMSO) (ATCC, Manassas, VA) to a final concentration of 20 mM. Topotecan 
hydrochloride was purchased from GlaxoSmithKline (Philadelphia, PA) and solubilized 
to a final concentration of 20 mM in sterile water. CellTiter 96® AQueous MTS assay 
reagents were purchased from Promega (Madison, WI). 
 
 
2.2.2. Cell culture 
 
Neuroblastoma cell lines NB1691, NB1643, NBEBC1, SHSY-5Y, SKNAS, and 
SKNBE2C were cultured in antibiotic-free RPMI-1640 medium (Cellgro®, Manassas, 
VA) containing 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA) and 1% 
L-Glutamine (Invitrogen, Carlsbad, CA) at 37°C in 5% CO2.  
 
 
2.2.3. Cell viability assay  
 
Briefly, cells were seeded in 100 l phenol red-free RPMI-1640 medium 
(Cellgro®, Manassas, VA) in 96-well plates and allowed to attach overnight. Cells were 
treated with increasing concentrations of nutlin-3a alone or increasing concentrations of 
topotecan in combination with nutlin-3a for 6 hours. After 6 hours, topotecan was washed 
off and cells were incubated with or without nutlin-3a for additional 18 hours. Cell 
viabilities were tested by MTT assay or CellTiter 96® AQueous MTS assay following 
the manufacturer's protocol. IC50 values were calculated using ADAPT 5 (Biomedical 
Simulations Resources, Los Angeles, CA) [225].  
 
 
2.2.4. Synergy study  
 
Synergism, additive effects, and antagonism were assessed using the median 
effect method developed by Chou [226]. The combination index (CI) values at non-fixed 
nutlin-3a/topotecan concentration ratios were calculated using the commercially available 
software Calcusyn 2.1 (Biosoft, Cambridge, United Kingdom). CI values < 1.0 indicate 






2.2.5. qRT-PCR  
  
Cells were treated with 10 M nutlin-3a for 24 hours. Total RNA samples were 
extracted using Qiagen RNeasy® Plus Mini Kit (Valencia, CA) following manufacturer's 
instructions. RNA concentrations were quantified using Beckman DU-600 
spectrophotometer (Beckman Instruments Inc., Fullerton, CA). Genomic DNA 
elimination, RT reaction, and cDNA synthesis reaction were performed using the RT2 
First Strand Kit (SABiosciences, Frederick, MD) following the manufacturer's protocol.  
 
Primers used for RT-PCR analysis were synthesized by the Hartwell Center at St. 
Jude. Children’s Research Hospital. For MDR1, the forward primer sequence was 
CCATCATTGCAATAGCAGG, and the reverse primer sequence was 
TGTTCAAACTTCTGCTCCTGA. For GAPDH control, the forward primer sequence 
was AAGGACTCATGACCACAGTCCAT, and the reverse primer sequence was 
CCATCACGCCACAGTTTCC. SYBR Green qPCR Master Mix was purchased from 
SABiosciences (Frederick, MD). QRT-PCR reactions were performed on ABI Prism® 
7700 Sequence Detection System (Applied Biosystems, Foster City, CA). The reactions 





2.2.6. Western blots 
 
Cells were lysed in M-PER Mammalian Protein Extraction Reagent (Thermo 
Scientific, Rockford, IL) following manufacturer’s instructions. Protein concentrations 
were determined using the BCA protein assay (Thermo Scientific Rockford, IL). 8-16 μg 
of proteins were resolved by SDS PAGE gels (4–12% gradient Bis/Tris NuPage gels) 
(Invitrogen, Carlsbad, CA) with MOPS SDS running buffer (Invitrogen, Carlsbad, CA) 
before transferring onto 0.45 μm pore size InvitrolonTM PVDF membranes (Invitrogen, 
Carlsbad, CA). P-gp was detected using the mouse monoclonal antibody clone C-219 
(Alexis Biochemicals, San Diego, CA).  -actin (AC-15, Sigma–Aldrich, St. Louis, MO) 





2.2.7. Statistical analysis 
 
All data were expressed as mean ± standard deviation. Data were analyzed for 
statistical significance using Student’s t-test. Differences with p < 0.05 were considered 




2.3.1. Effect of single agent nutlin-3a on the cell viability of neuroblastoma cell lines 
 
p53 wild-type NB1691, NB1643 and p53 mutant SKNBE2C cells were incubated 
with increasing concentrations of nutlin-3a alone for 24 hours. IC50 values were 
determined by MTT assay (Figure 2-1). The IC50 values of nutlin-3a in p53 wild-type 
cells NB1691 and NB1643 were 3.99 ( ± 0.12) M and 4.29 ( ± 0.20) M, respectively. 
p53 mutant SKNBE2C cells were resistant to nutlin-3a treatment, with IC50 value of 26 
( ± 295.62) M.  
 
 
2.3.2. Combination of nutlin-3a with topotecan in NB1691 cells 
 
NB1691 cells were incubated with increasing concentrations of topotecan in 
combination with DMSO control or 2M nutlin-3a for 6 hours. After 6 hours, cells were 
washed with drug-free media. Media containing either DMSO control or 2M nutlin-3a 
was added back to the wells for additional incubation of 18 hours. IC50 values were 
determined by MTT assay (Table 2-1). Without combination, the IC50 value of topotecan 
in NB1691 cells was 8.39 ( ± 1.04) M. Combination of topotecan with nutlin-3a resulted 
in a 4.7-fold reduction of IC50 to 1.79 ( ± 0.29) M.  
 
 
2.3.3. Synergistic effect of nutlin-3a in combination with topotecan 
 
To study the interaction of nutlin-3a and topotecan in NB1691 cells, NB1691 
cells were incubated with various concentrations of nutlin-3a and topotecan. Cells were 
treated with nutlin-3a and topotecan for 6 hours. After 6 hours, cells were washed with 
drug-free media. Media containing various concentrations of nutlin-3a was added back to 
the wells for additional incubation of 18 hours. IC50 values were determined by MTS 
assay. 
 
The CI values at non-fixed nutlin-3a/topotecan concentration ratios were 
calculated using Calcusyn 2.1. The calculated CI values were listed in Table 2-2. 
Fractional effect is defined as the fraction of cells affected by nutlin-3a and topotecan 
combination. A fractional effect value of 0 indicates no inhibition, and a fractional effect 
value of 1 indicates 100% inhibition of cell viability. When topotecan concentrations 





Figure 2-1.  Effect of single agent nutlin-3a on the cell viability of neuroblastoma 
cell lines  
 
p53 wild-type NB1691, NB1643 and p53 mutant SKNBE2C cells were incubated with 
increasing concentrations of nutlin-3a alone for 24 hours. IC50 values were determined by 
MTT assay in 5 replicates. IC50 values were calculated using ADAPT 5. Values are 





Table 2-1. Combination of nutlin-3a with topotecan in NB1691 cells 
 
Treatment IC50  
(M) 
SD  Confidence interval (95%) 
(M) 
Topotecan 8.39 1.04 [  6.32, 10.46  ] 
Nutlin-3a +topotecan 1.79 0.29 [  1.21, 2.38  ]  
 
NB1691 cells were incubated with increasing concentrations of topotecan in combination 
with DMSO control or 2 M nutlin-3a for 6 hours. After 6 hours, cells were washed with 
media. Media containing either DMSO control or 2M nutlin-3a was added back to the 
wells for additional incubation of 18 hours. IC50 values were determined by MTT assay. 
Combination of topotecan with nutlin-3a resulted in a 4.7-fold reduction of IC50 to from 
8.39 ( ± 1.04) M to 1.79 ( ± 0.29) M. IC50 values were calculated using ADAPT 5. 





Table 2-2. Synergistic effect of nutlin-3a in combination with topotecan 
 
Topotecan (M) Nutlin-3a (M) Fa Combination index (CI) 
0.39 1.25 0.46 0.39 
0.39 2.50 0.46 0.64 
0.39 5.00 0.46 1.15 
0.39 10.00 0.68 0.71 
0.39 20.00 0.67 1.56 
0.78 1.25 0.47 0.46 
0.78 2.50 0.47 0.70 
0.78 5.00 0.47 1.17 
0.78 10.00 0.72 0.60 
0.78 20.00 0.74 1.05 
1.56 1.25 0.59 0.26 
1.56 2.50 0.59 0.40 
1.56 5.00 0.59 0.68 
1.56 10.00 0.75 0.50 
1.56 20.00 0.75 1.00 
3.13 1.25 0.67 0.19 
3.13 2.50 0.67 0.28 
3.13 5.00 0.67 0.47 
3.13 10.00 0.77 0.44 
3.13 20.00 0.77 0.88 
6.25 1.25 0.72 0.17 
6.25 2.50 0.72 0.24 
6.25 5.00 0.72 0.39 
6.25 10.00 0.77 0.47 
6.25 20.00 0.78 0.87 
12.50 1.25 0.68 0.40 
12.50 2.50 0.68 0.49 
12.50 5.00 0.68 0.67 
12.50 10.00 0.71 0.79 
12.50 20.00 0.73 1.23 
25.00 1.25 0.68 0.73 
25.00 2.50 0.68 0.82 
25.00 5.00 0.68 1.01 
25.00 10.00 0.64 1.96 
25.00 20.00 0.63 3.06 
50.00 1.25 0.55 6.39 
50.00 2.50 0.55 6.56 
50.00 5.00 0.55 6.89 
50.00 10.00 0.59 4.71 
50.00 20.00 0.75 1.46 
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Table 2-2. (Continued) 
 
Topotecan (M) Nutlin-3a (M) Fa Combination index (CI) 
100.00 1.25 0.63 4.91 
100.00 2.50 0.63 5.03 
100.00 5.00 0.63 5.26 
100.00 10.00 0.62 6.34 
100.00 20.00 0.64 5.87 
 
NB1691 cells were incubated with various concentrations of nutlin-3a and topotecan. 
IC50 values were determined by MTS assay. The CI values at non-fixed 
nutlin-3a/topotecan concentration ratios were calculated using commercially available 
software Calcusyn 2.1. CI values < 1.0 indicate synergism, CI values = 1.0 indicate 










2.3.4. MDR1 gene expression change after nutlin-3a treatment 
 
Since wild-type p53 was reported to repress the MDR1 promoter [97-99], the 
synergism observed in NB1691 may be explained by the reduction of MDR1 gene 
expression. To evaluate the effect of nutlin-3a on the MDR1 gene expression, we 
performed qRT-PCR in a panel of neuroblastoma cell lines after 10 M nutlin-3a 
treatment for 24 hours. Compared to control cells, a 3-fold reduction of MDR1 gene 
expression was observed in MDM2-amplified NB1691 cells. In contrast, a 1.54-fold 
increase of MDR1 gene expression was observed in p53 mutant SKNBE2C cells. There 
were no changes in the gene expression of MDM2 non-amplified p53 wild-type cells 
SHSY5Y, NB1643, and NBEBC1 cells and p53 null SKNAS cells. Results in Figure 2-2 
represent pooled data of three independent experiments.  
 
 
2.3.5. P-gp protein expression after nutlin-3a treatment 
 
In addition to evaluating MDR1 expression at the message level, P-gp expression 
at the protein level was evaluated using western blot. Results in Figure 2-3 suggest 
reduced protein expression of P-gp in NB1691 and NBEBC1 cells. No increased P-gp 





Our preliminary studies showed that targeting MDM2-p53 interaction using 
nutlin-3a reduced cell growth in neuroblastoma cells. p53 wild-type cells were much 
more sensitive to nutlin-3a treatment compared to p53 mutant cells. When nutlin-3a was 
combined with topotecan, a synergistic effect was observed when topotecan 
concentrations were < 25 M. When topotecan concentrations were > 25 M, the 
nutlin-3a and topotecan combination caused antagonistic effect. This is the first study 
looking at nutlin-3a and topotecan interaction in neuroblastoma cell lines. Synergism has 
been reported in other tumor types, such as retinoblastoma [24] and intraocular 
melanoma [227], when nutlin-3a and topotecan were combined. Topotecan 
concentrations tested in those two studies did not include levels > 25 M.  
 
 To investigate possible mechanism of synergy, we performed qRT-PCR and 
western blot and found reduced MDR1 expression at both the message level and protein 
level in MDM2-amplified NB1691 cells. In MDM2 non-amplified NBEBC1 cells, 
although no MDR1 gene expression change was observed, western blot data showed 
reduced expression of P-gp protein. Since topotecan is a substrate of P-gp, synergism 







Figure 2-2.  MDR1 gene expression change after nutlin-3a treatment 
 
MDR1 gene expression changes after 10 M nutlin-3a treatments were evaluated using 
qRT-PCR in a panel of neuroblastoma cell lines. Values are presented as mean ± SD. 






Figure 2-3.  P-gp protein expression change after nutlin-3a treatment 
 
Western blot from cell lysates collected after 24-hr nutlin-3a treatment (20 μM) probed 
using antibody c219 against P-gp. -actin was used as loading control. Data are 




mentioned that this study was preliminary, and more independent experiments are needed 
to support the change of P-gp expression at the protein level. 
 
 As we were planning to conduct further research to study the effect of nutlin-3a 
on P-gp function, Michaelis et al. in the meantime reported that nutlin-3a inhibited P-gp 
function and reversed vincristine resistance in neuroblastoma and rhabdomyosarcoma 
cells independent of p53 status [228]. The mechanism of inhibition proposed in that study 
was competitive inhibition. In the current study, we evaluated a different mechanism of 
action of nutlin-3a on P-gp. Instead of competitive inhibition, nutlin-3a inhibited the 




CHAPTER 3. MDM2 ANTAGONIST NUTLIN-3A REVERSES 
MITOXANTRONE RESISTANCE BY INHIBITING BREAST CANCER 





Pre-clinical investigations of the utility of nutlin-3 treatment of cancer cells have 
focused primarily on the consequences of p53 reactivation in cells due to disruption of 
the MDM2/p53 interaction. Nutlin-3 is a racemic mixture of nutlin-3a (active 
enantiomer) and nutlin-3b (inactive enantiomer) with nutlin-3a having 150-fold more 
affinity to MDM2 [17]. Indeed, single agent nutlin-3 treatment has shown anti-cancer 
efficacy in xenograft models of solid tumors, including osteosarcoma, prostate cancer, 
KSHV lymphomas, retinoblastoma, and neuroblastoma [17, 24, 25, 40, 43]. Recently, 
other effects of nutlin-3 treatment have been reported, including anti-angiogenic effects 
[214, 229, 230] and radiosensitization of cancer cells under low oxygen conditions [29]. 
Furthermore, nutlin-3 has been reported to sensitize cancer cells to co-treatment with 
selected anti-cancer drugs, independent of p53 status, by enhancing the ability of 
anticancer drugs to activate apoptosis [223], and also by reversing P-gp mediated MDR 
[228]. Understanding the mechanism behind this nutlin-3 sensitization of resistant cancer 
cells would significantly enhance the use of nutlin-3 in combination with other 
anti-cancer drugs in a broad range of tumor types.  
 
Drug-resistance is a major obstacle in the treatment of cancer, and ATP-binding 
cassette (ABC) transporters play an integral role in the development of multi-drug 
resistance [231]. ABC transporters utilize the energy of ATP hydrolysis to pump 
anti-cancer agents out of the cell, thus reducing the intracellular drug concentration. 
Recently, Michaelis et al. observed that nutlin-3 can interfere with the function of the 
ABC transporters P-pg and MRP1 [228]. Nutlin-3 treatment reversed drug resistance in 
neuroblastoma and rhabdomyosarcoma cells over-expressing these transporters in vitro 
when combined with cytotoxic drugs that are P-gp and MRP1 substrates. These data 
suggest that nutlin-3 functionally inhibits the action of drug efflux proteins, thereby 
sensitizing cells to treatment with cytotoxic agents that are substrates of these efflux 
proteins.  
 
BCRP belongs to the ABC transporter family. Although it is possible that 
nutlin-3a may modulate the activity of BCRP, so far, the effect of nutlin-3a on BCRP has 
not been reported. The present study investigates whether nutlin-3a inhibits BCRP, thus 
sensitizing cells to enhanced killing by anti-cancer drugs that are BCRP substrates. Using 
MTS assays, we determined that nutlin-3a reverses resistance to the BCRP substrate 
mitoxantrone. Combination index calculations indicated synergism when nutlin-3a was  
 
 
 Reprinted with permission. Zhang, F., et al., MDM2 antagonist nutlin-3a reverses 
mitoxantrone resistance by inhibiting breast cancer resistance protein mediated drug 
transport. Biochemical Pharmacology, 2011. 82(1): p. 24-34. 
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used in combination with the anticancer agent mitoxantrone, a BCRP substrate, in 
osteosarcoma cells over-expressing BCRP. Based on these observations, we performed a 
series of studies to comprehensively investigate the effect of nutlin-3a treatment on 
BCRP expression and function. Our studies strongly suggest that nutlin-3a inhibits BCRP 
efflux and can reverse BCRP-related drug resistance, but is not a BCRP substrate.  
 
3.2. Materials and Methods 
 
 
3.2.1. Reagents  
 
Nutlin-3a and nutlin-3b were synthesized in the Department of Chemical Biology 
at St. Jude Children’s Research Hospital, Memphis, TN and were solubilized in dimethyl 
sulfoxide (DMSO) (ATCC, Manassas, VA) to a final concentration of 30 mM. The 
chemical structure of nutlin-3 has been published previously [17]. Hoechst 33342 and 
G-418 (Geneticin®) were purchased from Invitrogen (Carlsbad, CA). Mitoxantrone and 
Ko143 were purchased from Sigma-Aldrich (St. Louis, MO). Fumitremorgin C (FTC) 
was purchased from Alexis Biochemicals (San Diego, CA). 
 
 
3.2.2. Cell culture 
 
Saos-2 (human osteosarcoma) cells stably transfected with human wild-type 
(Arg482) BCRP or control vector pcDNA3.1 were generously donated by Dr. John 
Schuetz (St. Jude Children’s Research Hospital, Memphis, TN) [62, 232]. MDCK 
II- pCDNA3.1 and MDCK II-BCRP cells were generously donated by Dr. Mark Leggas 
(University of Kentucky, Lexington, KY). Cells were cultured in complete Dulbecco’s 
Modified Eagle’s Medium (DMEM) (Invitrogen, Carlsbad, CA) containing 10% fetal 
bovine serum (FBS) (Invitrogen, Carlsbad, CA), 1% L-glutamine (Invitrogen, Carlsbad, 
CA), and maintained with G418 (0.5 mg / ml) (Invitrogen, Carlsbad, CA). Cells were 
cultured in G418-free complete media at the time of seeding for individual experiments. 




3.2.3. Cell viability assay (MTS)  
 
 Cells were seeded in 100 l phenol red-free medium (Invitrogen, Carlsbad, CA) 
in 96-well plates and allowed to attach overnight. Cells were treated with increasing 
concentrations of nutlin-3a alone or increasing concentrations of mitroxantrone in 
combination with 0 μM, 20 μM or 50 μM nutlin-3a for 24 hours. Cell viabilities were 
tested by the CellTiter 96® AQueous MTS assay (Promega, Madison, WI) following the 
manufacturer's instructions. IC50 values were calculated using ADAPT 5 (Biomedical 





3.2.4. Median effect analysis 
 
 To characterize the interaction between mitroxantrone and nutlin-3a in 
Saos-2-BCRP and Saos-2-pcDNA3.1 cells, data were analyzed using the median effect 
method developed by Chou [226]. The combination index (CI) values at non-fixed 
nutlin-3a/mitoxantrone concentration ratios were calculated using the commercially 
available software Calcusyn 2.1 (Biosoft, Cambridge, United Kingdom). CI values < 1.0 




3.2.5. Intracellular accumulation and efflux of mitoxantrone by confocal imaging 
 
 Vector control and BCRP expressing Saos-2 cells were seeded on 35 mm glass 
bottom dishes (MatTek Corporation, Ashland, MA) and allowed to attach for 36 hours. 
Cells were pre-incubated with nutlin-3a for 15 minutes in DMEM+ (DMEM with 2% 
FBS, 1 mM HEPES buffer) at 37°C. Mitoxantrone (1 μM) was added and cultures were 
incubated for an additional 1 hour. Cells were washed with ice cold HBSS+ (HBSS with 
2% FBS, 1 mM HEPES buffer) containing nutlin-3a and intracellular accumulation was 
measured using confocal imaging. An Eclipse C1si confocal, configured on an Eclispe 
TE2000 microscope (Nikon, Melville, NY) with a Plan Fluor 40 × NA 1.3 lens was used. 
Excitation was from a 642 nm diode laser, and the emission was collected through a 
675/50 nm bandpass filter. 
 
 
3.2.6. Hoechst 33342 dye accumulation and efflux studies by flow cytometry 
 
 Hoechst 33342 dye was used as a BCRP substrate. Vector control and BCRP 
over-expressing Saos-2 and MDCKII cells were cultured to 60-70% confluence. Single 
cell suspensions were pre-incubated in DMEM + with nutlin-3a, nutlin-3b or FTC at 
varying concentrations for 15 minutes at 37°C. Hoechst 33342 dye was then added to a 
final concentration of 5 g / ml and cells were incubated at 37°C for 1 hour. Cells were 
pelleted and resuspended in ice cold HBSS+ containing nutlin-3a, nutlin-3b or FTC. 
Intracellular Hoechst 33342 fluorescence signals were detected by a 440/40 nm band pass 
filter with UV laser excitation and the data were collected and analyzed using a BD 
LSRII flow cytometer (BD, San Jose, CA). Data were processed as previously described 
[62]. Propidium iodide (PI) (Roche Applied Science, Mannheim, Germany) was added as 




3.2.7. Intracellular accumulation and efflux of Hoechst 33342 by widefield imaging 
 
 Vector control and BCRP expressing Saos-2 cells were seeded on 35 mm glass 
bottom dishes and allowed to attach for 36 hours. Cells were pre-incubated with nutlin-3a 
 47 
 
or nutlin-3b in DMEM+ for 15 minutes at 37°C. Hoechst 33342 (1 μg / ml) was added 
and cultures were incubated for an additional 1 hour. Cells were washed with ice cold 
HBSS+ containing nutlin-3a or nutlin-3b and intracellular accumulation was measured 
using widefield fluorescence imaging. Hoechst 33342 imaging was performed on a Nikon 
Eclipse TE2000 microscope with a Plan Fluor 40 × NA 0.6 lens and a standard DAPI 
filter set.  
 
 
3.2.8. Western blots 
 
 Total cellular protein was extracted from cell pellets and protein concentrations 
were determined by BCA assay (Thermo Scientific, Rockford, IL). Proteins were 
resolved by SDS PAGE [4-12% gradient Bis/Tris NuPage gels (Invitrogen, Carlsbad, 
CA)] with MOPS SDS running buffer (Invitrogen, Carlsbad, CA) before transferring onto 
InvitrolonTM PVDF membranes (Invitrogen, Carlsbad, CA). BCRP was detected using 
the rat monoclonal BXP-53 (Alexis Biochemicals, San Diego, CA). P-gp was detected 
using the mouse monoclonal antibody clone C-219 (Alexis Biochemicals, San Diego, 
CA). Beta-actin (AC-15, Sigma-Aldrich, St. Louis, MO) was used as the loading control.  
 
 
3.2.9. Flow cytometry for BCRP  
 
PE conjugated mouse anti-BCRP (MAB4155P) (Millipore, Billerica, MA) 
antibody was used to detect protein expression by flow cytometry. Cells were treated 
with 50 μM nutlin-3a for 1 hour, harvested, and then 1.0 × 106 cells were resuspended in 
100 μL BD Fc BlockTM (BD Pharmingen, San Diego, CA) and incubated on ice for 30 
minutes. Cells were washed once and then stained with the primary antibody (anti-BCRP 
10 g / ml) at room temperature for 30 minutes. Cells were again washed and 
resuspended in a final volume of 0.5 ml. Cells were counterstained with 
4'-6-Diamidino-2-phenylindole (DAPI) (Invitrogen, Carlsbad, CA) and analyzed using a 
BD LSRII flow cytometer (BD, San Jose, CA).  
 
 
3.2.10.   BCRP localization 
 
 Localization of BCRP was evaluated using confocal imaging analysis. Cells were 
grown on 35 mm glass bottom dishes and treated with 50 μM nutlin-3a for 90 minutes. 
After incubation, cells were washed with HBSS and fixed with 4% paraformaldehyde 
(Polysciences, Warrington, PA) for 15 minutes at room temperature. After 3 HBSS 
washes, cells were permeabilized using 0.2 % Triton X-100 (Sigma-Aldrich, St. Louis, 
MO) diluted in HBSS for 5 minutes then washed in HBSS. After 3 HBSS washes, 
Image-iT™ FX signal enhancer solution (Invitrogen, Carlsbad, CA) was applied and the 
dishes were incubated at room temperature for 30 minutes. After 3 additional HBSS 
washes, mouse monoclonal antibody against BCRP (BXP-21, Alexis Biochemicals, San 
Diego, CA) (1:1000 diluted in HBSS + 2% bovine serum albumin) was added and cells 
were incubated for an additional 60 minutes at room temperature. Cells were then stained 
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with Alexa Fluor® 555 goat anti-mouse IgG secondary detection conjugate (1:500) 
(Invitrogen, Carlsbad, CA) at room temperature for 90 minutes. Finally, ProLong® 
Gold-DAPI anti-fade reagent (Invitrogen, Carlsbad, CA) was added and wells were 
cover-slipped. BCRP localization was assessed using confocal imaging. A Nikon Eclipse 
C1si confocal configured on an Eclipse TE2000 microscope with a Plan Fluor 40 × NA 
1.3 lens was used. Excitation was from a 561 nm diode laser and emission was collected 
through a 605/75 nm bandpass filter. 
 
 
3.2.11.   Intracellular accumulation of nutlin-3a 
 
 MDCKII-pcDNA3.1 and MDCKII-BCRP cells were seeded into 6-well plates at a 
density of 0.5 × 105 cells/well in 2 ml of complete DMEM without G418. When cells 
were 80~90% confluent, nutlin-3a was added at increasing final concentrations of 0, 1, 5, 
10, 20, and 50 μM. Cells were incubated at 37° C for 1 hour. Cells were then washed 
with ice cold phosphate buffered saline (PBS) twice, and scraped off in 1ml ice cold 
homogenization buffer (5 mM HCOONH4, pH 7.0). Cell pellets were then lysed on ice 
by sonicating for approximately 10 sec/well twice with a 15 sec interval using a 4710 
series ultrasonic homogenizer (Cole-Parmer, Chicago, IL, USA). Intracellular nutlin-3a 
concentrations were measured using the LC-MS/MS method published previously [233]. 
Final intracellular nutlin-3a concentrations were normalized to total protein content as 
measured by BCA assay. 
 
 
3.2.12.   Bi-directional transport across MDCKII monolayer cells 
 
 MDCKII-pCDNA3.1 and MDCKII-BCRP cells were seeded at 1 × 106 cells per 
well in 0.4 μm, 12 mm Transwell® permeable inserts (Corning Incorporated, Corning, 
NY). Transport assays were performed when cells reached consistent trans-epithelial 
electrical resistance [234] values (between 200-300 μ cm2), indicating that the cells had 
formed a confluent polarized monolayer. Prior to transport assays (30 minutes), the 
medium in the donor and receiver chambers was removed and replaced with transport 
buffer (HBSS/25 mM HEPES). Buffer containing nutlin-3a was added to either the apical 
or the basolateral side of the monolayer with or without the BCRP-specific inhibitor 
Ko143. Samples were removed for the determination of initial nutlin-3a concentrations, 
and then at 30, 60, 120, and 240 minutes. 50 μl aliquots were removed from the either the 
basolateral or apical compartments. The volume removed was replaced immediately with 
fresh transport buffer. Nutlin-3a samples were prepared and analyzed using LC-MS/MS 
method as described above.  
 
 The apparent permeability (Papp) is calculated using Equation 3-1 [234]: 
 




where Vr is the volume of buffer in the receiver chamber; C0 is the initial drug 
concentration in the donor chamber; S is the surface area of monolayer; dC/dt is the 
linear slope of drug concentration in the receptor chamber over time. 
 
 The efflux ratio (RE) is calculated using Equation 3-2:  
 
RE = (Papp,B-A/Papp,A-B)                                          Eq. 3-2 
 
where Papp,B-A is the apparent permeability of drug transport from basolateral to apical 
side and Papp,A-B is the apparent permeability of drug transport from apical to basolateral 
side.  
 
 The final efflux ratio (R) is calculated using Equation 3-3: 
 
    R = (MDCK II-BCRP efflux ratio)/(MDCK II-pcDNA 3.1 efflux ratio)       Eq. 3-3 
 
 
3.2.13.   ATPase assay 
 
 BCRP ATPase activity was determined using SB BCRP HAM PREDEASY™ 
ATPase kit and SB defBCRP HAM PREDEASY™ Ctrl kit following the manufacturer's 
instructions (XenoTech, Lenexa, KS). The assay contains two different tests that are 
performed simultaneously on the same plate. In the activation test, BCRP substrates 
stimulate baseline vanadate-sensitive ATPase activity. In the inhibition test, inhibitors or 
slowly transported compounds may inhibit the maximal vanadate sensitive ATPase 
activity. Nutlin-3a was tested in both the activation and inhibition reactions at increasing 
concentrations (0.14, 0.41, 1.23, 3.70, 11.11, 33.33, 100, and 150 mol/L) for 10 minutes 
following the manufacturer's instructions. The assay was performed in triplicate. 
 
 
3.2.14.   Statistical analysis 
 
 All data expressed as mean ± standard deviation unless otherwise indicated. Data 
were analyzed for statistical significance using Student’s t test. Differences with p < 0.05 
were considered statistically significant. Linear and nonlinear regressions were performed 
using Prism 5 (GraphPad Software, La Jolla, CA). 
 
 
3.3. Results  
 
 
3.3.1. Nutlin-3a sensitizes BCRP expressing cells to mitoxantrone treatment 
 
 Saos-2-pcDNA3.1 and Saos-2-BCRP cells were incubated with nutlin-3a alone or 
in combination with the anti-cancer agent mitoxantrone, a BCRP substrate. IC50 values 
were determined by MTS assay. BCRP over-expression did not confer resistance to 
 50 
 
nutlin-3a as a single agent. The IC50 value of nutlin-3a was 45.8 ( ± 2.6) μM for 
Saos-2-BCRP and 43.5 ( ± 3.0) μM for Saos-2-pcDNA3.1 (p > 0.05) (Figure 3-1).  
 
 BCRP expression did confer resistance to mitoxantrone in the Saos-2 cell lines. 
The Saos-2-pcDNA3.1 cells exhibited sensitivity to mitoxantrone with an IC50 of 2.0 
( ± 0.1) μM while the BCRP over-expressing Saos-2 cells had a markedly increased 
mitoxantrone IC50 of 165.8 ( ± 21.9) μM (P < 0.001) (Figure 3-2). To determine the 
effect of nutlin-3a on potentially reversing this mitoxantrone resistance, Saos-2-BCRP 
cells were co-incubated with 20 μM or 50 μM nutlin-3a and increasing concentrations of 
mitoxantrone (0.01-300 μM) for 24 hours. A dramatic reduction in the mitoxantrone IC50 
from 165.8 ( ± 21.9) μM to 7.6 ( ± 0.5) μM (21.8-fold, p < 0.001) and 1.0 ( ± 0.07) μM 
(165.8-fold, p < 0.001) was observed in the Saos-2-BCRP cells after treatment with 20 
and 50 μM nutlin-3a, respectively (Figure 3-2). In Saos-2-pcDNA3.1 cells, only a 
moderate reduction of mitoxantrone IC50 was observed, from 2.0 ( ± 0.01) μM to 1.4 
( ± 0.1) μM (1.4-fold, p < 0.001) and 0.6 ( ± 0.4) μM (3.3-fold, p < 0.001) (Figure 3-2). 
Using combination index analysis, we evaluated whether the combination of nutlin-3a 
and mitoxantrone was synergistic. Combination index (CI) values around 1 indicate that 
two drugs have an additive effect. A CI < 1 indicates synergy, and a CI > 1 indicates 
antagonism [226]. The fractional effect is the ratio of the effect (growth inhibition) 
caused by the two compounds in combination to that of one of the compounds alone. A 
fractional effect value of 0 indicates no inhibition and fractional effect value of 1 
indicates 100% inhibition of cell viability. In contrast to Saos-2-pcDNA3.1 cells where 
synergism, additivity, and antagonism can be observed on different nutlin-3a: 
mitoxantrone ratios (Figure 3-3A), moderate (++) to strong (++++) synergism [226] was 
observed in Saos-2-BCRP cells with combination index (CI) values between 0.132 and 
0.798 at all nutlin-3a: mitoxantrone ratios tested (Figure 3-3B). These results indicate 
that the synergistic effect observed in Saos-2-BCRP cells induced by the 
nutlin-3a/mitoxantrone combination is dependent on the presence of BCRP. 
 
 
3.3.2. Nutlin-3a inhibits BCRP-mediated transport of mitoxantrone 
 
 To determine whether the observed reduction in the mitoxantrone IC50 of the 
Saos-2-BCRP cells co-treated with nutlin-3a was due to increased exposure to 
mitoxantrone, intracellular accumulation of mitoxantrone was measured by confocal 
imaging. Saos-2-pcDNA3.1 and Saos-2-BCRP cells were co-incubated with 1 μM 
mitoxantrone and increasing concentrations of nutlin-3a (0 to 50 μM) for 1 hour. In the 
absence of nutlin-3a, little mitoxantrone accumulation was observed in Saos-2-BCRP 
cells (Figure 3-4), indicating active efflux by BCRP, whereas under the same conditions, 
mitoxantrone was retained in the Saos-2-pcDNA3.1 cells. Treatment with nutlin-3a 
resulted in a dose-dependent increase in the intracellular mitoxantrone accumulation in 








Figure 3-1.  BCRP expression does not confer resistance to nutlin-3a treatment 
 
Saos-2-BCRP and Saos-2-pcDNA3.1 cells were incubated with increasing concentrations 
of nutlin-3a (0.1-150 μM) for 24 hours. Cell viabilities were tested by MTS assay in 
triplicate. IC50 values were calculated using ADAPT 5. Values are presented as mean 







Figure 3-2.  Co-treatment of cells with nutlin-3a and mitoxantrone strongly 
reverses BCRP mediated drug resistance to mitoxantrone 
 
Saos-2-pcDNA3.1 and Saos-2-BCRP cells were treated with increasing concentrations of 
mitoxantrone (0.01-300 μM) in combination with 20 and 50 μM nutlin-3a for 24 hours as 
described in the methods. Cell viabilities were determined by MTS assay in triplicate. 
ADAPT 5 was used to calculate IC50. Values are presented as mean ± SD. *** P < 0.001. 







Figure 3-3.  Synergistic effects of nutlin-3a in combination with mitoxantrone 
 
The combination index (CI) values at non-fixed nutlin-3a/mitoxantrone concentration 
ratios were calculated using commercially available software Calcusyn 2.1.  CI 
values < 1.0 indicate synergism,  CI values = 1.0 indicate additive effect, and 	 CI 
values > 1.0 indicate antagonism. Fractional effect is defined as the fraction of cells 
affected by nutlin-3a and mitoxantrone combination. A fractional effect value of 0 
indicates no inhibition and a fractional effect value of 1 indicates 100% inhibition of cell 
viability. Data are representative of two independent experiments. 
 
A. For Saos-2-pcDNA3.1 cells, at 20 μM nutlin-3a, additive effect and antagonism were 
observed. At 50 μM nutlin-3a, when nutlin-3a: mitoxantrone ratios were > 100:1, both 
additive and synergistic effects were observed; when nutlin-3a: mitoxantrone ratios were 
< 100:1, antagonism was observed. 
 









Figure 3-4.  Nutlin-3 treatment strongly increases the intracellular accumulation 
of mitoxantrone in Saos-2-BCRP cell lines 
 
Nutlin-3 treatment strongly increases the intracellular accumulation of mitoxantrone in 
Saos-2-BCRP cell lines. Confocal imaging of mitoxantrone (red) in Saos-2-pcDNA3.1 
and Saos-2-BCRP cells in the presence increasing concentrations of nutlin-3a for 60 
minutes suggested dose dependent restoration of intracellular mitoxantrone accumulation. 




3.3.3. Nutlin-3a inhibits BCRP-mediated transport of Hoechst 33342 
 
To determine whether nutlin-3a could also reduce the efflux of other BCRP 
substrates, the intracellular retention of another prototypical BCRP substrate, Hoechst 
33342, was measured by flow cytometry in Saos-2 cells with and without BCRP 
expression. As BCRP over-expressing Saos-2 cells were incubated with increasing 
amounts of nutlin-3a, a dose-dependent decrease in the efflux of Hoechst 33342 was 
observed. Co-incubation of cells with nutlin-3a and Hoechst 33342 for 1 hour resulted in 
an almost complete inhibition of Hoechst 33342 efflux in Saos-2-BCRP cells (Figure 
3-5A). This inhibition was comparable to that seen with the BCRP-specific inhibitor FTC 
(Figure 3-6). Co-incubation of cells with enantiomer nutlin-3b resulted in the same 
reduction in Hoechst 33342 efflux (Figure 3-7). Only events from viable cells were used 
for data analysis, and there was no difference in the viability between BCRP 
over-expressing and the vector control cells treated with either nutlin-3a or nutlin-3b 
(Figure 3-8). To determine if the reduced Hoechst 33342 efflux was dependent on p53 
status, accumulation studies were also performed in p53 wild-type MDCKII cells. The 
results indicated that nutlin-3a also reverses the Hoechst 33342 efflux in a p53 wild-type 
cell line in a dose dependent manner (Figure 3-5B). Hence, nutlin-3a inhibition of 
BCRP-mediated transport of Hoechst 33342 is independent of cellular p53 status. In 
addition to the abrogation of efflux observed with flow cytometric methods, results from 
fluorescence imaging also demonstrated after treatment with nutlin-3a that Hoechst 
33342 intracellular accumulation was dramatically restored in the Saos-2-BCRP cell line 
to levels comparable to Saos-2-pcDNA3.1 control cells (Figure 3-9). Treatment of cells 
with the enantiomer nutlin-3b resulted in the same reduction in Hoechst 33342 efflux, 
demonstrating that the two enantiomers have comparable effects on BCRP function 
(Figure 3-9).  
3.3.4. Nutlin-3a treatment does not alter BCRP expression or localization 
 
 To determine whether increased accumulation and sensitivity to mitoxantrone 
were a result of nutlin-3a inducing an alteration in BCRP protein levels, 
Saos-2-pcDNA3.1 and Saos-2-BCRP cells were treated at the highest nutlin-3a dose level 
used for functional studies (50 μM; 1 hr) and BCRP protein levels were measured. As 
shown in Figure 3-10, both western blot (Figure 3-10A) and flow cytometric analysis 
(Figure 3-10B) demonstrated that total cellular protein levels of BCRP in Saos-2-BCRP 
cells were not altered in the presence of nutlin-3a. Since nutlin-3 has been shown to affect 
P-gp function, levels of P-gp protein were also assessed by western blot. Although Saos-2 
cells do not express detectable levels of P-gp [232, 235], it is possible that nutlin-3a 
treatment may up-regulate P-gp expression. As expected, nutlin-3a treatment did not 
significantly alter the expression of P-gp in either Saos-2-pcDNA3.1 or -BCRP cells 
(data not shown). Additional studies using confocal microscopy confirmed no obvious 









Figure 3-5.  Nutlin-3a dose-dependently inhibits BCRP efflux of Hoechst 33342, 
independent of p53 status
 
p53 null Saos-2-pcDNA3.1 and Saos-2-BCRP, and p53 wild-type MDCKII-pcDNA3.1 
and MDCKII-BCRP cells were incubated with increasing concentrations of nutlin-3a or 
vehicle control in the presence of Hoechst 33342 for 60 minutes. Data are representative 
of at least three independent experiments. 
 
A. Dose-dependent reduction of Hoechst 33342 efflux after nutlin-3a treatment assayed 
by flow cytometry in Saos-2 and MDCKII cells. 
 
B. Quantitative assessment of nutlin-3a effects from representative flow cytometry 









Figure 3-6.  Effect of FTC on the BCRP efflux of Hoechst 33342 
 
Saos-2-pcDNA3.1 and Saos-2-BCRP cells were incubated with DMSO or FTC in the 
presence of Hoechst 33342 for 60 minutes. Data are representative of one experiment 






Figure 3-7.  Effect of nutlin-3b on efflux of Hoechst 33342 
 
Saos-2-pcDNA3.1 and Saos-2-BCRP cells were incubated with DMSO or nutlin-3b in 
the presence of Hoechst 33342 for 60 minutes. Data are representative of one experiment 







Figure 3-8.  Viability ratio of Saos-2-BCRP/ Saos-2-pcDNA3.1 during the Hoechst 
33342 efflux study  
 
Saos-2-pcDNA3.1 and Saos-2-BCRP cells were incubated with 50 μM nutlin-3a or 
nutlin-3b in the presence of Hoechst 33342 for 60 minutes. Data are representative of one 






Figure 3-9.  Nutlin-3 treatment increases the intracellular accumulation of 
Hoechst 33342 in Saos-2-BCRP cell lines
 
Wide-field fluorescence imaging of intracellular Hoechst 33342 (blue) in 
Saos-2-pcDNA3.1 and Saos-2-BCRP cells in the presence or absence of 50 μM nutlin-3a 
or nutlin-3b for 60 minutes. Treatment with nutlin-3a and nutlin-3b strongly restored the 








Figure 3-10.  Nutlin-3a does not alter levels of BCRP protein expression  
 
A. Western blot analysis of the BCRP protein expression following nutlin-3a treatment 
(N, 50 μM nutlin-3a; D, equal volume DMSO). BCRP protein was detected using the 
monoclonal antibody BXP-53.  
 
B. Flow cytometric analysis of the cell-surface expression of BCRP in response to 
nutlin-3a treatment. Cells were stained with the PE conjugated mouse anti-BCRP 
antibody (MAB4155P) and subjected to analysis. DAPI was added to cells to indicate 







Figure 3-11.  Nutlin-3a does not alter cellular localization of BCRP in Saos-2 cells 
Confocal images taken of Saos-2 cells expressing BCRP treated with vehicle (DMSO) or 
nutlin-3a (50 μM, 90 minutes). Red represents BCRP protein and blue represents nuclear 





3.3.5. Nutlin-3a is not a substrate for BCRP 
 
 To test whether nutlin-3a is a BCRP substrate and thus inhibits BCRP function by 
competing with other substrates for transport, we examined the intracellular accumulation 
of nutlin-3a in MDCKII-pcDNA 3.1 and MDCKII-BCRP cells. Cells were incubated 
with 0, 1, 5, 10, 20, and 50 μM nutlin-3a at 37° C for 1 hour. No significant difference 
was observed in the amount of intracellular nutlin-3a between the two cell types at any 
concentration (up to 50 μM) (p > 0.05) (Figure 3-12). These data suggest that nutlin-3a is 
not a substrate of BCRP. In addition to the intracellular accumulation assay, bidirectional 
transport studies were conducted using BCRP over-expressing and pcDNA3.1 vector 
control MDCKII cells. Nutlin-3a concentrations from either the apical or basolateral 
compartment were measured by LC-MS/MS and concentration vs. time plots were 
generated (Figure 3-13). The calculated R (REBCRP/REpcDNA3.1) was 0.04, much less than 
the efflux ratio of 2, which is considered the cutoff for a drug to be a substrate [234]. 
Additionally, concentration vs. time plots of nutlin-3a in the presence and absence of the 
BCRP specific inhibitor Ko143 (5 μM) indicated that BCRP does not transport nutlin-3a 
(data not shown). Using the criteria outlined in the decision tree supported by the 
International Transporter Consortium, nutlin-3a is not a substrate of BCRP [47].  
 
 
3.3.6. Nutlin-3a inhibits the ATPase activity of BCRP 
 
 To investigate inhibition as a mechanism for the nutlin-3a-induced reduction in 
efflux of BCRP substrates, BCRP ATPase activity in response to nutlin-3a treatment was 
measured using a previously described ATPase activity assay [93, 94]. BCRP transporter 
activity was determined by assaying both activation and inhibition in the presence of a 
known activator of the transporter (i.e., sulfasalazine). Increasing concentrations of 
nutlin-3a (0.1 μM  to 150 μM) did not stimulate ATPase activities from the baseline 
measurements (data not shown). In the corresponding inhibition assay, however, higher 
concentrations of nutlin-3a demonstrated a strong capacity to inhibit ATPase activity 
(Figure 3-14).  
3.4. Discussion 
 
 This is the first study demonstrating that nutlin-3a inhibits BCRP activity. Our 
data suggest that resistance to mitoxantrone can be strongly reversed by nutlin-3a in 
BCRP over-expressing cells. Nutlin-3a treatment resulted in a dose-dependent increase in 
the intracellular accumulation of BCRP substrates in BCRP over-expressing cells. To 
understand the mechanism behind these observations, a series of studies were performed 
that clearly demonstrated nutlin-3a inhibited BCRP efflux independent of p53, without 
altering BCRP protein expression or subcellular localization. Additionally, studies 
examining the intracellular accumulation of nutlin-3a along with bi-directional transport 
across MDCKII monolayer cells supported the conclusion that nutlin-3a is not a substrate 







Figure 3-12.  No difference in intracellular accumulation of nutlin-3a in the 
presence of BCRP 
 
MDCKII-pcDNA3.1 and MDCKII-BCRP cells were incubated with 0, 1, 5, 10, 20, and 
50 μM nutlin-3a for 60 minutes. Intracellular nutlin-3a concentrations were determined 
by LC-MS/MS as previously described and normalized to total protein content. Data are 









Figure 3-13.  Trans-epithelial transport of nutlin-3a (10 µM) in MDCKII-
pcDNA3.1 and MDCKII-BCRP cells indicates nutlin-3a is not a substrate of BCRP 
 
Nutlin-3a was administered to one compartment (basolateral or apical) at time 0. After 
30, 60, 120, and 240 minutes, the concentrations of nutlin-3a appearing in the opposite 
compartment were measured by LC-MS/MS. Data are presented as mean ± SD of 
triplicates.  
 
A. Translocation from the basolateral to the apical compartment. Data are representative 
of two independent experiments. 
 
B. Translocation from the apical to the basolateral compartment. Data are representative 






Figure 3-14.  Nutlin-3a dose dependently inhibited BCRP ATPase activity 
 
The relative vanadate-sensitive ATPase activity of Sf9 insect cell membranes 
over-expressing wild-type ABCG2 is represented as mol Pi/mg protein/min in the 
presence of increasing concentrations of nutlin-3a with a known BCRP substrate, 




Multi-drug resistance is a major obstacle in the success of cancer treatment. 
Among the ABC family of transporters, P-gp, MRP1, and BCRP are three major 
members associated with multidrug resistance [53]. BCRP, the most recently discovered 
among these three major transporters [53, 236], confers resistance to many anti-cancer 
drugs used clinically including mitoxantrone, methotrexate, doxorubicin, daunorubicin, 
topotecan, and SN38 [237, 238]. Utilization of an agent such as nutlin-3a, which inhibits 
BCRP, in combination with an anti-cancer agent that is a BCRP substrate (such as 
mitoxantrone or topotecan) may potentially increase the intracellular drug levels and lead 
to greater anti-tumor activity. In fact, when nutlin-3 was combined with the BCRP and 
P-gp substrate topotecan for 5 days, an 82-fold reduction in the tumor burden of 
retinoblastoma was reported [24]. It is important to note however that synergistic effects 
may differ depending on the cell type or co-administered drug, and antagonism may be 
observed if the schedule of administration were to change [239, 240]. 
 
 Since nutlin-3a re-activates p53 in cells co-expressing MDM2 [17, 39], the 
question exists of whether the reversal of ABC transporter activity is dependent on the 
p53 pathway. Our data along with the previous study by Michaelis et al. clearly 
demonstrate that the inhibition of ABC transporter efflux by nutlin-3 occurs 
independently of cellular p53 status [228]. Also supporting this conclusion is the 
observation that nutlin-3b, the non-active enantiomer, demonstrated BCRP inhibition 
comparable to the active enantiomer nutlin-3a. 
 
 Michaelis et al. demonstrated that nutlin-3 stimulated P-gp ATPase activity in 
isolated membranes and exerted a negative effect on P-gp activity by acting as a 
competing substrate [228]. In contrast, our studies demonstrate by multiple approaches 
that nutlin-3a does not act as a competitive inhibitor of BCRP. First, the amount of 
intracellular nutlin-3a and the nutlin-3a IC50 were unaffected by the over-expression of 
BCRP. Second, the calculated efflux ratios from the bidirectional transport assay were 
< 2 in MDCKII cells. Lastly, nutlin-3a did not activate ATPase activity as measured by 
released inorganic phosphate (Pi) in a BCRP over-expression system. On the other hand, 
nutlin-3a dose dependently decreased the ATPase activity in the inhibition assay. 
 
 Previous studies have implicated BCRP translocation from the plasma membrane 
to the cytoplasm as a mechanism by which BCRP function can be regulated [241]. We 
demonstrated in our studies via western blot and flow cytometry that neither total BCRP 
protein levels nor the subcellular localization of BCRP changed during the time period 
that efflux studies were conducted. These findings are important because since BCRP is 
involved in drug disposition and many other physiological processes in the body, using a 
drug that alters BCRP expression and/or localization would likely have global effects. 
Specifically, BCRP is expressed at the blood brain barrier, placenta, gastrointestinal tract, 
kidney, liver and biliary tract, and BCRP activity is important for intestinal absorption, 
brain penetration, renal elimination and hepatobiliary excretion of substrates. 
 
 Along with BCRP, P-gp and MRP1 also play a critical role in pharmacokinetic 
interactions of anti-cancer agents, affecting the absorption, distribution, metabolism, and 
excretion (ADME) processes. Concomitant treatment of elacridar (GF120918), an 
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inhibitor of BCRP and P-gp, resulted in a 2.4 fold increase in bioavailability and systemic 
exposure of oral topotecan in adults with cancer [242]. Similarly, concomitant treatment 
with gefitinib, another inhibitor of BCRP and P-gp, increased bioavailability of oral 
irinotecan in mice [243] and in pediatric patients with refractory solid tumors [244]. Our 
lab recently demonstrated that gefitinib enhanced topotecan penetration in gliomas in 
mice [245]. As an inhibitor of multiple major efflux transporters including BCRP, P-gp 
and MRP1, nutlin-3a may have impact on pharmacokinetics, pharmacodynamics, and 
importantly the safety of many clinically used drugs. Therefore, it is crucial that 
transporter related drug-drug interactions be carefully addressed in future preclinical 
studies.  
 
In conclusion, this is the first study demonstrating that nutlin-3a inhibits BCRP 
activity. Our data show that nutlin-3a dose dependently inhibits BCRP-mediated 
transport of multiple BCRP substrates and synergistically reverses the drug resistance to 
anticancer agent mitoxantrone. The likely mechanism of this effect is the inhibition of 
BCRP ATPase activity, as we have clearly demonstrated through multiple lines of 
investigation that nutlin-3a is not a substrate of BCRP. Thus, using nutlin-3a in 
combination with anti-cancer agents that are BCRP or other ABC transporter substrates 
would require additional studies to identify potentially significant drug-drug interactions 





CHAPTER 4. WHOLE-BODY PHYSIOLOGICALLY BASED 
PHARMACOKINETIC MODEL FOR NUTLIN-3A IN MICE AFTER 





Nutlin-3a (2-piperazinone, 4-[[(4S,5R)-4,5-bis(4-chlorophenyl)-4,5-dihydro-2-[4 
methoxy-2-(1-methylethoxy)phenyl]-1H-imidazol-1-yl]carbonyl]-) is currently 
undergoing preclinical investigation as a p53 reactivation agent. While many cancers and 
tumor types express mutated forms of p53 [246], a subset of cancers, and particularly 
pediatric tumors, retain wild-type p53 [211]. In these cases, cancer cells frequently 
employ other mechanisms to abrogate p53 function. One such mechanism is 
over-expression or amplification of the murine double minute (MDM2) protein. This 
molecule binds directly to p53 to accelerate its turnover and inhibits transcription of 
downstream targets, including cell cycle and apoptotic genes [8, 218]. Disruption of the 
MDM2–p53 interaction is proposed as a novel strategy for treatment of cancers that do 
not have p53 alterations [21, 247]. 
 
Nutlins are a class of small molecules that target the p53-binding pocket of 
MDM2 [17, 248]. Treatment of multiple types of cancer cells including leukemias [26, 
41], neuroblastoma [221], rhabdomyosarcoma [249] and retinoblastoma [250] with 
nutlin-3a induces p53-dependent cell cycle arrest and cell death, whereas in normal cells, 
nutlin-3a exposure leads to cell cycle arrest without cell death [22]. Nutlin-3a has 
antitumor activity in a preclinical xenograft model of neuroblastoma [43] and was tested 
in several other preclinical models of malignancies [17, 40]. 
 
To date, the pharmacokinetics of nutlin-3a has not been reported. An 
understanding of the systemic disposition of nutlin-3a, as well as the distribution to target 
tissue or tumor sites, will provide a rational basis for the selection of dosage regimens for 
preclinical models. Additionally, since the in vitro tumor cell line sensitivities to 
nutlin-3a have been determined, pharmacokinetic modeling can be used to determine the 
dose and schedule necessary to achieve appropriate unbound nutlin-3a concentrations at 
the tumor site. One approach to analyze these data is the use of whole-body 
physiologically-based pharmacokinetic model (PBPK) models, which are based on 
anatomical compartments and blood flow. 
 
Thus, we performed pharmacokinetic studies to develop a PBPK model 
describing the disposition of nutlin-3a in plasma and tissues, including adipose, adrenal 
gland, bone marrow, brain, liver, lung, intestine, muscle, retina, spleen, and vitreous 
fluid. The PBPK model was used to perform simulations, which in combination with in 
vitro cell sensitivity data provided rationale for choosing dosing regimens for mouse 
 
 Reprinted with permission. Zhang, F., et al., Whole-body physiologically based 
pharmacokinetic model for nutlin-3a in mice after intravenous and oral 




models of common childhood cancers, including retinoblastoma, neuroblastoma, 
rhabdomyosarcoma, and acute lymphoblastic leukemia (ALL). 
 
 





Adult C57BL/6 mice were purchased from Charles River (Bar Harbor, Maine, 
USA). Mice were housed in a temperature-controlled room on a normal 12-h light/dark 
cycle, with free access to water and standard laboratory food. All procedures were 
approved by the St. Jude Institutional Animal Care and Use Committee and conducted in 
accordance with the NIH guidelines for the care and use of laboratory animals. The 






cis-Nutlin-3a (98% purity, Lot No.: 08252008) was synthesized and supplied by 
the Department of Chemical Biology and Therapeutics at St. Jude Children’s Research 
Hospital (Memphis, TN, USA). The oral formulation [17] used in the pharmacokinetic 
studies was nutlin-3a suspended in 2% Klucel (Conservation Resources International, 
LLC, Springfield, VA, USA) and 0.5% Tween-80 (Sigma-Aldrich, St. Louis, MO, USA), 
and the IV formulation used was nutlin-3a in 4% ethanol, 35% propylene glycol (Fisher 
Scientific, Pittsburgh, PA, USA), 10% PEG-400 (Sigma-Aldrich), and 51% PBS 
(Mediatech INC, Manassas, VA, USA). The internal standard ketoconazole was 
purchased from Sigma-Aldrich. Blank murine plasma was obtained from Hilltop Lab 




4.2.3. Blood to plasma ratio 
 
Pooled whole blood from healthy male C57BL/6 mice was collected into heparin 
tubes. Nutlin-3a was spiked into aliquots of whole blood at final concentrations of 0.1, 1, 
10, and 100 μM in triplicate. Samples were mixed and incubated at 37°C for 30 minutes 
with additional mixing every 5 minutes. After incubation, 50 μl of whole blood was 
removed and immediately placed on dry ice. The remainder of the sample was 
centrifuged at 16,000 rpm for 2 min and a 50 μl plasma sample was removed and 
immediately placed on dry ice. All samples were stored at -80°C until analysis. The 
blood to plasma concentration ratio was calculated using the using Equation 4-1: 
 
	




where CP is the concentration in plasma, CWB is the concentration in whole blood. 
 
 
4.2.4. Nutlin-3a protein binding studies 
 
Equilibrium dialysis was performed in a 96-well dialysis plate with a 5-KDa 
cut-off membrane (Harvard Apparatus, Holliston, MA, USA). For mouse plasma and cell 
culture media protein binding, 200 μl of PBS buffer was added into the wells on one side 
of the membrane and an equivalent volume of male C57BL/6 plasma or cell culture 
media (RPMI with 10% FBS and 2 mM L-glutamine) containing varying concentration 
of nutlin-3a was added into the wells on the opposite side. The plate was sealed and fixed 
onto a dual plate rotator (Harvard Apparatus) at 37ºC in a humidified incubator 
containing 5% CO2. Equilibrium dialysis was performed at 0.2, 20, and 100 M nutlin-3a 
in triplicate for 24 h. For vitreous protein binding, 150 μl rodent vitreous containing 0.5 
M nutlin-3a was added to the sample side and equal volume of PBS buffer was added to 
the buffer side. Equilibrium dialysis was performed in triplicate for 24 h. The samples 
were analyzed using the analytical method described below. The bound concentration 
was considered equal to the plasma side and the free concentration equal to the PBS side 






                                         Eq. 4-2 
 
where Cp,b is the bound plasma concentration, Bmax is the quantity of plasma protein 




4.2.5. Drug administration and sample collection 
 
Two pharmacokinetic studies were conducted. For the first pharmacokinetic 
study, 145 adult C57BL/6 mice (128 male and 17 female) were divided into three groups: 
two oral dosage groups (100 and 200 mg/kg) and one IV dosage group (10 mg/kg). 
Nutlin-3a was administered given as a single bolus dose by oral gavage or by i.v. tail vein 
injection. Each dosing group (n = 5 mice) and vehicle controls had 9 collection time 
points (0.5, 1, 2, 4, 8, 12, 24, 36, and 48 h). At each time point, blood was collected under 
isoflurane anesthesia via cardiac puncture. Whole blood samples were centrifuged 
immediately at 12,000 g at 4 ºC for 5 minutes to separate plasma. Simultaneously, tissue 
samples including brain, vitreous, retina, liver, spleen, and bone marrow were dissected. 
Each sample was put on dry ice immediately after collection and stored at -80ºC until 
analysis.  
 
In the second pharmacokinetic study, 210 adult male C57BL/6 mice were used. 
Two oral dosages (50 and 100 mg/kg) and two i.v. dosages (10 and 20 mg/kg) were 
administered. Each dosing group (n = 5 for 10 mg/kg IV and 100 mg/kg oral dosages; 
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n = 10 for 20 mg/kg IV and 50 mg/kg oral dosages) and vehicle control had 7 collection 
time points (0.5, 1, 2, 4, 8, 12, and 24 h for the IV dosing; 0.5, 1, 2, 4, 8, 12, and 16 h for 
oral dosing). Serial plasma samples were collected from all mice. Tissue samples, 
including brain, lung, liver, spleen, kidney, adrenal gland, muscle, fat, intestine from 3 
mice per time point from the 20 mg/kg IV group, were collected. Each sample was put on 
dry ice immediately after the sample collection and stored at -80ºC until analysis.  
 
 
4.2.6. Quantitative analysis of nutlin-3a  
 
Nutlin-3a mouse plasma and tissue samples were analyzed based on our 
previously published liquid chromatography electrospray ionization tandem mass 
spectrometry analytical method [233]. The lower limit of quantification (LLOQ) for 
nutlin-3a in plasma after protein precipitation was 10 ng/ml and the LLOQ for nutlin-3a 
after liquid-liquid extraction was 0.25 ng/mL. Within-day and between-day precisions for 
protein precipitation and liquid-liquid extraction were 
 5% and accuracies ranged from 
91.6 to 104.8%. For each sample type (cerebellum, brain, vitreous, retina, lung, heart, 
liver, gall bladder, spleen, kidney, adrenal gland, muscle, fat, bone marrow, intestine, 
whole blood, and PBS), standard curves and controls were generated using the 
corresponding untreated tissue or PBS to eliminate any matrix effect. For larger tissues, 
sections were cut, weighed, and stored on ice for further processing. 10 μL ice cold 
homogenization buffer (5 mM HCOONH4, pH = 7) were added per mg of tissue. For 
smaller tissue samples including vitreous, retina, adrenal gland, and gall bladder, the 
amount of homogenization buffer used was increased to a minimum volume of 70~100 
μL. Tissue samples were then sonicated on ice for 15 seconds, with 5 second intervals. 
The number of total sonications varied depending on the tissue types. Homogenated 
tissues and whole blood samples were extracted and analyzed using protein precipitation 
and the PBS samples were extracted using the liquid-liquid extraction method as 
described previously [233]. 
 
 
4.2.7. Whole body PBPK model development 
 
We developed a whole body PBPK model for nutlin-3a based on in vitro blood 
cell partitioning, plasma protein binding, and pooled concentration-time data from all 
plasma and tissue samples collected from both pharmacokinetic studies. This PBPK 
model consisted of a series of mass balance differential equations describing the 
concentration of nutlin-3a in various tissues, which were connected by blood flow. 
Physiological values for mouse organ size and blood flow are presented in Table 4-1. A 
schematic representation of the model is shown in Figure 4-1.  
 
Plasma concentrations were converted to whole blood concentrations based on the 
in vitro blood partitioning experiment. Unbound plasma concentrations were described 




Table 4-1. List of physiological parameters 
 
Tissue Symbol Mass (% body weight) QB (ml/h) Reference 
Blood BLO 4.9 839 [254] 
Adipose ADI 6.8 58.7 [254] 
Adrenal gland ADR 0.048 2.52 [254] 
Bone marrow MRW 5.8 92.3 [254] 
Brain BRA 1.65 27.7 [254] 
Intestines INT 3.62 109 [254] 
Liver LIV 5.49 16.8 [254] 
Lung LUN 0.73 839 [254] 
Muscle MUS 38.4 133 [254] 
Retina RET 0.04 3.16 Experimental; [255] 
Spleen SPL 0.35 9.48 [254] 
Vitreous fluid VIT 0.035 0* Experimental 
Remainder RES 29.9 256.9 - 
 





Figure 4-1.  Schematic diagram of PBPK model for nutlin-3a in mice 
 
C,b = bound drug concentration, C,f = free drug concentration. Arrows connecting 









where Cp,u is the unbound plasma concentration, Cp is the total plasma concentration, and 
Bmax and KA were determined from in vitro plasma protein binding studies. The unbound 





                                                    Eq. 4-4 
 
Most organs fit well to a perfusion-limited model, and thus were described by 
Equation 4-5: 
 
12  34536  72  '489 :
5
5
(                                       Eq. 4-5 
 
where Vi is the volume of organ, Ai is the amount of drug in the organ, Ci is the 
concentration in the organ, Ki is the partition coefficient, and CART is the concentration of 
arterial plasma.  
 
Liver blood flow (QLIV) was the sum of the blood flow to the hepatic artery, 
spleen, and liver, and the concentration of blood entering the liver (CBLO, LIV) was based 
on the arterial concentration and the venous outflow of the portal circulation (Equation
4-6). The liver contained an elimination term (ke) for metabolism, based on experiments 
showing that nutlin-3a is metabolized by mouse liver microsomes (K. Guy, unpublished): 
 
1;<=  34>?@36  7;<=  A;B;<= :
>?@
>?@
C : DE  489          Eq. 4-6 
 
The intestine was modeled with a separate lumen and tissue compartment. 
Absorption from the lumen was assumed to be linear based on an absorption rate constant 
(ka) (Equation 4-7): 
 
1<F9  34?GH36  DI  J<F9                                       Eq. 4-7 
 
The eye was fit to a two-compartment model consisting of the retina and vitreous. 
Input into the vitreous was by diffusion from the retina. The following equations were 
used for the retina and vitreous (Equation 4-8 and Equation 4-9):  
 
18K9  34LMH36  78K9  A489 :
LMH
LMH
C : NJ=<9  A8K9 : @?H@?HC         Eq. 4-8 
 
1=<9  34@?H36  NJ=<9  '8K9 :
@?H
@?H
(                             Eq. 4-9 
 




All tissues that were not sampled were lumped together in a residual 
compartment. Modeling this compartment as perfusion-limited did not adequately 
describe the multi-exponential profile of nutlin-3a. Therefore, the residual compartment 
was modeled as diffusion-limited, with the vascular space assumed to be 5% of the 
residual volume. The equations for the residual vascular space and tissue are the 
described using Equation 4-10 and Equation 4-11: 
 
18KO;B  34LMH36  78KO  $489 : 8KO;B% : NJ8KO  A8KO :
LMP
LMP
C Eq. 4-10 
 
18KO  34LMP36  NJ8KO  A8KO :
LMP
LMP
C                           Eq. 4-11 
 
The input into the venous pool of blood was modeled as the sum of the output 
from all tissues except the lung. The volume of the venous pool was fixed to 75% of the 
total blood volume. The lungs received all venous input and the arterial input was the 
output from the lungs (Equation 4-12): 
 
1;QF  34>RG36  7;B  A=KF :
>RG
>RG
C                          Eq. 4-12 
 
The arterial concentrations were based on the output from the lungs, and 
contained an additional saturable elimination term (Equation 4-13): 
 
1489  34LH36  7;B  A
>RG
>RG
: 489C : =SLH LH                  Eq. 4-13 
 
Elimination terms in both the blood compartment and liver compartment were 





After development of the PBPK model, tissue concentrations were simulated with 
NONMEM after multiple oral and intravenous doses at 50, 100, 200, and 400 mg/kg 
given both once daily and twice daily. The AUC0-24 at steady state was calculated with 
the log-linear trapezoidal method applied to the simulated data. Bioavailability was 






4.3.1. Blood to plasma partitioning and plasma protein binding of nutlin-3a 
 
Blood to plasma partitioning showed an average blood/plasma concentration ratio 
of 0.70, indicating that 30% of nutlin-3a partitions to blood cells (Figure 4-2A). Binding 




Figure 4-2.  Analysis of nutlin-3a characteristics in murine blood 
A. Nutlin-3a blood cell partitioning. Nutlin-3a was spiked into murine whole blood at 
various concentrations, and incubated 30 min at 37ºC. In one aliquot, nutlin-3a was 
measured in whole blood, and in another aliquot nutlin-3a was measured in the plasma. 
 
B. Nutlin-3a plasma protein binding. Nutlin-3a was spiked into murine plasma at various 
concentrations and incubated for 30 min at 37ºC. Plasma protein binding was determined 
by equilibrium microdialysis and is expressed as the percent of the total nutlin-3a plasma 






μM to 0.118 at 300 μM (Figure 4-2B). Nonlinear regression of unbound versus bound 
plasma concentrations using the Langmuir equations resulted in a Bmax of 286 and a KA 
of 0.085 (Figure 4-3).  
 
 
4.3.2. Nutlin-3a pharmacokinetics in mice 
 
Plasma and tissue concentrations of nutlin-3a were measured from 0 to 48 h in 
mice following a single i.v. dose of 10 or 20 mg/kg or a single oral dose of 50, 100, or 
200 mg/kg. After oral administration, nutlin-3a tissue concentrations rose rapidly to reach 
a maximum value at approximately 2 h. Nutlin-3a concentrations in the intestine, liver, 
and spleen were higher than those in the plasma, concentrations in adipose, adrenal gland, 
lung, muscle, and retina were similar to plasma concentrations, and concentrations in the 
brain, bone marrow, and vitreous were significantly lower than in the plasma (Figure
4-4). 
 
Rapid elimination was observed in the 10 mg/kg IV dosage group. At higher 
dosages, slower elimination was observed at higher concentrations, indicating saturable 
elimination of nutlin-3a. After 24 h, all data were below the limit of quantitation of the 
assay. Models with linear elimination, Michaelis-Menten elimination, and combined 
linear and Michaelis-Menten elimination were fit to the data. Ultimately, the combination 
of both linear and Michaelis-Menten elimination had the best fit to the data. The 
concentration-time data of nutlin-3a in all modeled tissues are plotted against the model 
predicted concentrations in Figure 4-5 (data not shown for oral 50 mg/kg dosage group, 
since only plasma was collected). The estimated pharmacokinetic parameters are listed in 
Table 4-2.  
 
Using the final model, we simulated nutlin-3a plasma concentrations after 
multiple doses on a once-daily and twice-daily schedule (Figure 4-6). Little to no 
accumulation was predicted to occur on a once daily schedule with IV or oral dosages up 
to 400 mg/kg. For twice daily dosing, steady state was predicted to occur within three 
doses, but accumulation would remain minimal. The predicted accumulation (Cmin single 
dose/Cmin at steady state) was dose-dependent and at 200 mg/kg is 1.5-fold for IV 
administration and 1.3-fold for oral administration. The AUC0-24 at steady state increased 
in an approximately dose-proportional manner and the AUC0-24 was approximately 
twice as high with twice-daily dosing versus once-daily dosing (Figure 4-7).  
 
Predicted bioavailability was dose- and schedule -dependent and ranged from 
75% at 25 mg/kg once-daily to 91% at 400 mg/kg once-daily. Bioavailability was 








Figure 4-3.  Nutlin-3a binding to murine plasma proteins 
Bound and unbound nutlin-3a plasma concentrations were determined with equilibrium 







Figure 4-4.  Comparison of actual plasma and tissue concentrations of nutlin-3a 
The median plasma concentrations are shown in each box as the dashed line and the 





Figure 4-5.  Concentration-time plots of nutlin-3a in tissues 
 
Symbols are data points from individual mice and the lines represent the model-predicted 
concentrations. Data from the 50 mg/kg oral group is not shown. Data below the lower 
























IIV ka 31.2% 
IIV ke 6.4% 
IIV Vmax 40.6% 






Figure 4-6.  Simulated concentration-time plot of plasma nutlin-3a after multiple 
oral doses with once-daily (QD) and twice-daily (BID) dosing 
 








Figure 4-7.  Plasma area under the concentration-time curve for 24 h at steady 
state (AUC0-24) versus nutlin-3a dosage when administered once daily (QD) and 
twice daily (BID) 
 




4.3.3. Application of PBPK model to the design of nutlin-3a dosing regimens in 
mice 
 
 The nutlin-3a PBPK model was used to choose dosing regimens of nutlin-3a to 
target (1) the retina and vitreous for models of retinoblastoma, (2) the adrenal gland for 
models of neuroblastoma, (3) the muscle for models of rhabdomyosarcoma, and (4) the 
plasma, spleen, and bone marrow for models of leukemia. The fraction of unbound 
nutlin-3a in tissues was assumed to be the same as the plasma unbound fraction, except 
for vitreous fluid that had a measured unbound fraction of 14.4%. Nutlin-3a binding to 
cell culture media was measured and shown to be nonlinear over the range of nutlin-3a 
concentrations used in in vitro cell cytotoxicity assays (Figure 4-8). The media protein 
binding value was used to convert the published nutlin-3a IC50 values of various cell lines 
[26, 249, 256] to the unbound IC50 (Table 4-3).  
 
The simulated unbound retina and vitreous nutlin-3a concentrations were 
compared to the in vitro unbound IC50 for the Weri1 retinoblastoma cell line in order to 
choose optimal dosing regimens for mouse models of retinoblastoma (Figure 4-9). Oral 
dosing of nutlin-3a twice daily was predicted to achieve unbound concentrations in the 
retina that were consistently above the unbound IC50 at dosages of 200 or 400 mg/kg 
(Table 4-4). However, even at 400 mg/kg twice daily, unbound concentrations in the 
vitreous were predicted to be above the unbound IC50 for only 17% of the time, and at 
lower dosages the concentration of unbound nutlin-3a never reached the unbound IC50 
level. Simulated concentration-time plots of unbound nutlin-3a after various dosing 
regimens are also shown in the adrenal gland for neuroblastoma (Figure 4-10), muscle 
for rhabdomyosarcoma (Figure 4-11) and plasma, bone marrow, and spleen for leukemia 





 Nutlin-3a is undergoing preclinical studies examining its potential efficacy for the 
treatment of several childhood malignancies. Nutlin-3a interrupts the p53-MDM2 
protein-protein interaction, which may lead to apoptosis or cell cycle arrest. Treatment of 
cells with nutlin-3a leads to reversal of multi-drug resistance [228], reduced cell 
migration [229], reduced angiogenesis [214, 229], radiosensitization of hypoxic cancer 
cells [29], and inhibition of tumor adaptation to hypoxia [257]. In this study, we 
developed a mouse PBPK model of nutlin-3a in plasma and multiple tissues of 
therapeutic interest. This is the first study to provide comprehensive pharmacokinetic 
data of nutlin-3a in any species. The design of our study included both oral and 
intravenous dosing at several dosage levels. This permitted the development of a robust 
model that accurately describes the disposition of nutlin-3a over a wide range of 
concentrations. The PBPK model was used to design rationale dosing regimens for 
preclinical models of several malignancies based upon achieving adequate cytotoxic 
nutlin-3a concentrations within the target organ. This approach is superior to optimizing 
dosing based solely on plasma concentrations since drug penetration to different organs 






Figure 4-8.  Nutlin-3a binding to cell culture media  
 
Bound and unbound nutlin-3a plasma concentrations were determined with equilibrium 
dialysis.  
 
A. The unbound fraction is shown with increasing total nutlin-3a concentrations. Bars 
represent the mean and error bars represent the standard deviation for one experiment 
performed in triplicate. 
 





Table 4-3. Nutlin-3a IC50 for cell survival in different cell types 
 








Weri1 retinoblastoma 1.1 0.21 72 Unpublisheda
IMR-32 neuroblastoma 3.02 0.77 72 [221] 
RMS-YM rhabodmyosarcoma 1.25b 0.26 48 [249] 
Primary MDM2-overexpressing 
ALL 
1.0b 0.20 44 [26] 
 
a. Mike Dyer, St. Jude Children’s Research Hospital, Memphis, TN. 
 




Figure 4-9.  Simulated concentration-time plot of unbound nutlin-3a in the retina 
and vitreous after multiple oral doses given once daily (QD) or twice daily (BID) 





Table 4-4. Percent time unbound tissue concentration is above unbound IC50
 
Cell line Tissue Time above IC50 (%) 
  QD BID 
  100 200 400 100 200 400 
Weri1 Retina 38 53 70 83 100 100 
 Vitreous 0 0 5 0 0 17 
IMR32 Adrenal 27 39 54 58 85 100 
RMS-YM Muscle 43 58 76 92 100 100 
ALL Plasma 43 57 75 90 100 100 
 Spleen 46 61 80 90 100 100 
 Marrow 0 23 35 12 48 77 
 




Figure 4-10.  Simulated concentration-time plot of unbound nutlin-3a in the 
adrenal gland after multiple oral doses given once daily (QD) or twice daily (BID) 
 
The horizontal lines represent the unbound IC50 of nutlin-3a for IMR-32 p53-wt 






Figure 4-11.  Simulated concentration-time plot of unbound nutlin-3a in the 
muscle after multiple oral doses given once daily (QD) or twice daily (BID) 
 
The horizontal lines represent the unbound IC50 of nutlin-3a for RMS-YM 







Figure 4-12.  Simulated concentration-time plot of unbound nutlin-3a in the 
plasma, bone marrow, and spleen after multiple oral doses given once daily (QD) or 
twice daily (BID) 
 
The horizontal lines represent the unbound IC50 of nutlin-3a for MDM2-overexpressing 





Our model describes the key pharmacokinetic properties of nutlin-3a in plasma: 
rapid absorption, high bioavailability, and saturable elimination that is very rapid at 
concentrations below 10 μM. Standard non-compartmental calculations of bioavailability 
of nutlin-3a were greater than 100% due to saturable elimination and different ranges of 
intravenous (10-20 mg/kg) and oral (50-100 mg/kg) dosages. Using the model to simulate 
the concentration-time profiles after the same dosage administered both intravenous and 
oral, we were able to estimate nutlin-3a oral bioavailability. Although we performed 
simulations after multiple doses, the model was based on data from only single doses of 
nutlin-3a, and therefore should be interpreted with caution. 
 
Nutlin-3a is a substrate for the ATP binding cassette (ABC) transporter 
P-glycoprotein (P-gp), but at higher concentrations can also inhibit P-gp efflux activity 
[228]. The inhibition of P-gp function may explain why nutlin-3a is capable of rapid 
absorption and high bioavailability despite being a P-gp substrate. It is also possible that 
inhibition of P-gp function underlies saturable nutlin-3a elimination, since P-gp can 
excrete drugs into both the bile and urine [47]. It is unknown whether nutlin-3a may also 
inhibit its own metabolism at higher concentrations.  
 
The partition coefficients showed a greater than 1000-fold difference between the 
tissues with the lowest and highest penetration. The liver and intestine showed the highest 
penetration. High penetration to the liver could be due to uptake transporters expressed at 
the hepatocyte membranes, which cause intracellular accumulation of nutlin-3a. The 
intestine had an atypical profile, possibly due to biliary excretion of nutlin-3a. The blood 
flow-limited model did not fit well to the intestinal concentration data, limiting the ability 
to accurately estimate the partition coefficient for this organ.  
 
Retinoblastoma is a tumor of the eye for which a number of orthotopic xenograft 
and genetic murine models have been developed [258]. Daily subconjunctival 
administration of nutlin-3a for 5 days was effective in a model of retinoblastoma and 
when combined with topotecan, an 82-fold reduction in tumor burden with no systemic or 
ocular side-effects was observed [24]. Our PBPK model shows that with the nutlin-3a 
regimen most commonly used in preclinical studies (200 mg/kg administered orally twice 
daily), unbound concentrations of nutlin-3a in the retina continuously exceeded the 
unbound IC50. However, due to poor penetration, the unbound IC50 was never achieved in 
the vitreous with this regimen and was achieved only transiently at 400 mg/kg twice 
daily, suggesting that subconjunctival dosing would be more appropriate for targeting 
retinoblastoma vitreous seeds [259, 260]. While the PBPK model cannot predict nutlin-3a 
pharmacokinetics after subconjunctival administration because the ocular absorption is 
not known, data from a limited experiment could be combined with the PBPK model to 
predict exposures in various tissues after ocular administration.  
 
At diagnosis, 98% of neuroblastoma tumors contain wild-type p53 [209-211], and 
thus these patients are likely to benefit from reactivation of this pathway. Sensitivity to 
nutlin-3a has been shown in multiple p53 wild-type neuroblastoma cell lines [221, 228]. 
Treatment of a subcutaneous UKF-NB-3rDOX20 xenograft model with twice-daily oral 
nutlin-3a (200 mg/kg) only partially inhibited tumor growth [43], despite good sensitivity 
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(IC50 of 5.56 μM) of these cells in vitro [228]. Because the racemic nutlin-3 mixture was 
used in this experiment, the assumed equivalent dose would be 100 mg/kg nutlin-3a twice 
daily. If unbound plasma concentrations are evaluated (since this was not an orthotopic 
xenograft), unbound nutlin-3a concentrations are predicted to be continually below the 
established IC50 with this regimen. However, the pharmacokinetic properties of the 
racemic mixture are unknown, and it is possible that nutlin-3b influences the saturable 
elimination or plasma protein binding of nutlin-3a. For a subcutaneous or orthotopic 
xenograft with similar cell sensitivity, 400 mg/kg oral nutlin-3a twice daily may result in 
better activity, since concentrations would continuously be above the IC50. Although the 
literature and our unpublished observations suggest that twice daily 200 mg/kg oral 
dosing is well tolerated in mice [43], further toxicity studies will need to be performed to 
determine whether higher dosages are tolerable. 
 
Nutlin-3a has also demonstrated cytotoxicity in rhabdomyosarcoma cell lines 
[228, 249], although it has not yet been tested in a preclinical model of 
rhabdomyosarcoma. Our model predictions show that the standard twice-daily oral 200 
mg/kg nutlin-3a regime sufficient to achieve unbound muscle nutlin-3a concentrations 
that were continuously above the IC50 for the RMS-YM cell line. Nutlin-3a 
concentrations above the IC50 for primary T-ALL cells [26, 41] was achieved in the 
plasma and spleen with a twice-daily regimen of 100 mg/kg oral nutlin-3a. However, 
penetration to the bone marrow was poor, and in order to target this compartment, 400 
mg/kg twice-daily is recommended, which is predicted to result in unbound nutlin-3a 
concentrations that are above the IC50 77% percent of the time.  
 
Although the model has a number of applications, it also has limitations. First, we 
did not perform experiments to determine the route of elimination of nutlin-3a. 
Preliminary unpublished observations indicate that nutlin-3a is metabolized by mouse 
liver microsomes, but a model with elimination only from the liver did not adequately fit 
the nutlin-3a plasma concentration-time data. Not modeling the elimination 
mechanistically could limit the ability to extrapolate the PBPK model to other species. 
Second, we performed all experiments in non-tumor bearing mice. Compared to normal 
tissues, the altered environment in tumors (e.g. vasculature, pH, interstitial fluid pressure) 
may lead to different local disposition. Although it was not feasible to perform 
pharmacokinetic studies in multiple preclinical models, data obtained from studies in 
tumor-bearing mice could be easily incorporated into this PBPK model. Another 
limitation is the assumption that the unbound fraction of nutlin-3a in tissues was 
equivalent to the unbound fraction in plasma. We did directly measure nutlin-3a binding 
in vitreous fluid, which is mostly water, but has a variety of proteins [261]. We also 
performed simulations at dosages beyond those used to develop the model (i.e. 400 
mg/kg). Although we were able to characterize the non-linear elimination at higher 
plasma concentrations, it is possible that there are unknown non-linear absorption or 
elimination processes occurring at this higher dosage which would make these model 
predictions inaccurate. 
 
In summary, we performed extensive mouse pharmacokinetic studies of nutlin-3a 
and developed a PBPK model, which was utilized to design nutlin-3a dosing regimens for 
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preclinical models of pediatric malignancies. Although there are limitations to 
extrapolating in vitro cytotoxicity data, this analysis provides a starting point for further 
pharmacokinetic/pharmacodynamic studies in tumor bearing mice. For models of 






CHAPTER 5. SUMMARY AND FUTURE DIRECTIONS 
 
 
The development of more effective and less toxic anti-cancer agents is a slow, 
high-risk, high-cost, and often high failure process. Potential new agents are emerging 
continuously from high throughput screening, however, only a small percentage of 
candidate molecules make their way from bench to bedside. Studies have shown that the 
success rate for the development of oncology drugs is much lower than that for drugs in 
other therapeutic areas [262]. In the last few years, the total capitalized cost per approved 
new drug molecule has risen to $0.8-1.3 billion [263-265]. For pediatric malignancies 
such as retinoblastoma, the small patient pool further hinders the drug development 
process because of the inability to conduct the clinical trials necessary to evaluate the 
different compounds. These difficulties necessitate better translational research, where 
preclinical studies can play an important role.  
 
Since oncology drugs are usually administered in combination, it is important to 
evaluate the interaction of drugs. Combining agents that act synergistically instead of 
antagonistically to inhibit cancer cell growth can have a positive impact on patient 
outcome, taking into consideration that oncology drugs have narrow therapeutic 
windows. Here we first reported that nutlin-3a synergistically inhibited neuroblastoma 
cell growth in combination with topotecan and synergistically inhibited BCRP 
over-expressing osteosarcoma cell growth in combination with mitoxantrone. Preclinical 
studies from our lab [212] and Michaelis et al. [228] suggested that nutlin-3a inhibited 
the function of three major efflux transporters BCRP, P-gp, and MRP1. These studies 
suggested that further in vivo drug-drug interaction studies should be conducted because 
nutlin-3a may significantly increase the systemic concentrations of agents that are 
substrates of these transporters. This may cause severe toxicity in clinic thus extra 
cautious are needed. We still do not know if nutlin-3a also inhibits other efflux or uptake 
transporters. In addition, because of the interaction of transporters and drug metabolizing 
enzymes, it is also possible that nutlin-3a may inhibit drug metabolizing enzymes. In fact, 
our preliminary study suggested that nutlin-3a may be an inhibitor of CYP3A4 (Figure
5-1). Thus, additional preclinical studies are needed to address the interaction of nutlin-3a 
with CYP3A4 substrates in vitro and in vivo. 
 
Reasons for attrition of oncology new chemical entities during clinical trials 
include incorrect hypothesis regarding the drug action on the disease, improper 
preclinical tumor model, improper clinical trial design, and drug toxicity. One additional 
explanation for this lack of effectiveness in translating laboratory science into efficient 
therapies is the scarce information on drug concentration within human tumor. The drug 
exposure at the target site, which is associated with efficacy, can be very different from 
the plasma exposure. Moreover, different tissues are likely to have different drug 
penetration characteristics. However, due to ethical and practical reasons, most current 
clinical trials do not measure drug concentrations directly in tumor or target tissues and 
instead rely on indirect assessment of drug exposure by measuring drug concentrations in 
surrogate compartments such as plasma. Thus, if one could develop an approach to 
reliably estimate human tumor or target tissue drug concentrations from preclinical data, 
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Figure 5-1.  Nutlin-3a inhibits the activity of CYP3A4 in vitro
 
Study was performed using Promega p450glo CYP3A4/Luciferin-IPA Assay (Madison, 






the use of drugs could be greatly improved. PK modeling and simulation is an example of 
such an approach. Once a preclinical model describing both plasma and target 
tissue/tumor concentration has been established, it can be scaled-up to humans to predict 
if the dosage necessary for a desirable target tissue or tumor concentration is practically 
achievable. If the answer is no, a "No-Go" decision should be considered to avoid trial 
failure and thus save precious resources. When the human plasma PK parameters are 
generated after either Phase 0 microdosing or after the Phase I clinical trial, the human 
plasma PK model can be updated to give more accurate prediction of human tissue/tumor 
concentration. This will allow the clinician to select more “effective” dosages, which are 
based upon exposures necessary for tumor effect.  
 
In this study, we conducted developed a mouse PBPK model of nutlin-3a in the 
plasma and multiple tissues of therapeutic interest. This is the first study to provide 
comprehensive pharmacokinetic data of nutlin-3a in any species. The design of our study 
included both oral and intravenous dosing at several dosage levels. This method 
permitted the development of a robust model that accurately describes the disposition of 
nutlin-3a in the plasma and organs over a wide range of concentrations. The PBPK model 
was used to suggest dosing regimens to attain putative cytotoxic nutlin-3a exposures in 
target tissues for retinoblastoma, neuroblastoma, rhabdomyosarcoma, and leukemia. 
Once nutlin-3a plasma concentration information in human is available (either by scaling 
or phase 0/I clinical trial), current PBPK model can be updated to predict nutlin-3a 
exposure in the human tissues. 
 
In future studies, nutlin-3a concentrations in preclinical models of pediatric 
tumors can be further assessed. One possible tumor to study is retinoblastoma. Nutlin-3a 
has shown promising efficacy in preclinical studies of retinoblastoma, and will be an 
excellent compound to use as a model for further PK-PD studies. Subconjunctival 
administration of nutlin-3a in combination with subconjunctival topotecan for 5 
consecutive days reduced the tumor burden by 82-fold in rats [24]. Subconjunctival 
nutlin-3a in combination with systemic topotecan demonstrated significant improvement 
in outcome in mice bearing orthotopic retinoblastoma tumor [42]. It has been shown that 
the dosing route of nutlin-3a has a great impact on its ocular distribution. PK studies 
suggested subconjunctival administration of nutlin-3a increased the vitreous exposure by 
2000-fold compared to systemic administration in non-tumor bearing mice [42]. 
However, the amount or extent of nutlin-3a reaching a retinoblastoma tumor in mouse 
models is still unknown, and it would not be feasible to obtain that data in patients. Thus, 
the overall goal of the proposed future study is to develop PK models of nutlin-3a 
disposition in retinoblastoma tumors after subconjunctival injection and systemic 
administration in orthotopic retinoblastoma xenograft. Both classical and PBPK model 
will be developed. Major challenges include determining retinoblastoma tumor blood 
flow, dealing with large variations of nutlin-3a concentrations in tumor, vitreous, and 
retina, and the structural complexity of the pharmacokinetic models. Other 
methodological issues to be addressed include the extremely small volume (< 8 μL per 
sample) of tissue samples (tumor, vitreous and retina), which could be an obstacle for 
both sample collection and LC-MS/MS analysis. However, when developed, these 
pharmacokinetic models would be the first to describe drug concentration in 
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retinoblastoma tumors with the ultimate goal to translate the findings to the design of 
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